Follow us on Twitter
twitter icon@FreshPatents


Infectious patents

      

This page is updated frequently with new Infectious-related patent applications.

Genetic markers for discrimination and detection of viruses causing infectious aquatic organism diseases, and discriminating and detecting the viruses using the same
The present invention relates to genetic markers for discrimination and detection of viruses causing infectious aquatic organism diseases, and a method of discriminating and detecting the viruses using the same, and more particularly to a method for discriminating or detecting viruses causing infectious aquatic organism diseases, the method comprising: selecting and amplifying a dna nucleotide sequence encoding a gene specific for viral hemorrhagic septicemia virus (vhsv), red sea bream iridovirus (rsiv) or infectious spleen and kidney necrosis virus (isknv), which is a virus causing red sea bream iridovirus disease, or koi herpesvirus (khv); hybridizing a peptide nucleic acid (pna) that specifically recognizes the amplification product; controlling the temperature of the hybridization product to obtain a temperature-dependent melting curve; and discriminating the viral type or detecting whether or not fish would be infected with the viral type by analyzing the obtained melting curve to determine a melting temperature.. .
National Institute Of Fisheries Science


Devices, detecting viable infectious agents in a fluid sample
Various devices, systems and methods for detecting a susceptibility of an infectious agent to an anti-infective are described herein. A method comprises introducing a fluid sample to a first surface and a second surface; exposing the first surface to a first solution; exposing the second surface to a second solution, wherein the second surface comprises an anti-infective; sampling the first solution after exposing the first solution to the first surface; sampling the second solution after exposing the second solution to the second surface; monitoring a first electrical characteristic of a first sensor exposed to the first solution sampled; monitoring a second electrical characteristic of a second sensor exposed to the second solution sampled; and comparing the first electrical characteristic and the second electrical characteristic to assess the susceptibility of the infectious agent to the anti-infective..
Avails Medical, Inc.


Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
Antagonistic tnfr superfamily polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory t cells (t-regs). For example, antibodies of the invention include antagonistic tnfr2 antibodies and antigen-binding fragments thereof, and can be used to suppress the t-reg-mediated deactivation of tumor reactive t-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases..
The General Hospital Corporation


Covalent diabodies and uses thereof
The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens.
Macrogenics, Inc.


Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
This invention relates to ly6g6f, vsig10, tmem25 and lsr proteins, which are suitable targets for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders, and drug development. This invention further relates to soluble ly6g6f, vsig10, tmem25 and lsr molecules, extracellular domains of ly6g6f, vsig10, tmem25 and lsr and conjugates, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders.
Compugen Ltd.


Sulfinylphenyl or sulfonimidoylphenyl benzazepines
Wherein x and r1 to r6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Pyrrolomycins and methods of using the same
Provided herein are pyrrolomycin derivatives, which can be used to modulate mcl-1, inhibit proliferation of bacteria and pathogens, as well as to treat infectious diseases and cancers.. .
Board Of Regents Of The University Of Nebraska


Modular mobile field-deployable laboratory for the detection, sequencing and analysis of emerging infectious diseases
A mobile field-deployable laboratory to more conveniently enable the detecting, sequencing and analyzing of biological agents at the point-of-need. This device enables field operators to go from sample to actionable information in the field without the need for an internet connection or grid-based power.
Mriglobal


Methods of treating cancer, infectious disease, and autoimmune disease using cxc chemokines
The current invention is related to the prevention and treatment of diseases including cancer, autoimmune disease, and infectious disease using cxc chemokines and the receptors to which they agonize. It has been found that certain chemokines, including cxcl4, cxcl9, cxcl10, and cxcl12 have various effects on toll-like receptors in various cell types and these can be utilized for disease treatment and prevention..
New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery


Exosomes for delivery of therapeutic agents
The present invention provides exosomes as drug delivery vehicles, compositions comprising a therapeutic agent encapsulated within such exosomes, methods of producing such exosomes and compositions thereof, as well as methods of delivering such exosomes and compositions to a specific patient tissue or organ. The present invention also provides methods of treating a disease, disorder, or condition such as cancer, an inflammatory disease, an infectious disease, an allergic disease, or an autoimmune disease, comprising administering to a patient in need thereof a provided therapeutic-loaded exosome or a pharmaceutical composition thereof..
Puretech Health Llc


Antibody molecules to pd-l1 and uses thereof

Antibody molecules that specifically bind to pd-l1 are disclosed. Combination therapies comprising the anti-pd-l1 antibody molecules are also disclosed.
President And Fellows Of Harvard College

Cyclic di-nucleotides as modulators of sting

Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer and as vaccine adjuvants..

Pd-1 peptide inhibitors

This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (pd-1). These peptides block the interaction of pd-1 with its ligand pd-l1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis..
Leidos, Inc.

Herbal composition for shrimp disease

A composition of herbal medicine which can be used for shrimp disease treatment, includes the following ingredients: lobelia chinensis lour, folium loropetali, composition x and fishmeal, crude protein, soymeal, powder, dextrin, glucose and minerals. The composition is used in manufacturing three different medicaments and for the different medicaments, the composition x includes one or more ingredients of astragalus, vitexin flower, elephantopus flower and coptis chinensis leaf.

Vaccine containing virus inactivated by green tea extract, and preparation method therefor

The present invention relates to a vaccine composition containing a virus inactivated by a green tea extract, and a preparation method therefor. According to the present invention, when a virus is treated with a green tea extract, there are simultaneous effects of virus inactivation and excellent immunogenicity maintenance, and thus an inactivated vaccine can be prepared by mixing the green tea extract of the present invention and a virus with a proliferative capacity, and infectious diseases caused by the corresponding virus can be effectively prevented since an immune reaction to the corresponding virus is induced when a vaccine composition prepared by the preparation method of the present invention is administered to a subject.
Industry-academic Cooperation Foundation, Yonsei University

Compositions and methods for modulating pro-inflammatory immune response

Provided herein are compositions and methods useful for increasing a pro-inflammatory immune response, treating an autoimmune disorder, inflammation, or transplant rejection in a mammal by activating a leukocyte immunoglobulin-like receptor (lilr) protein. Also provided are compositions and methods useful for increasing a pro-inflammatory immune response, treating cancer, and treating infectious disease in a mammal by blocking the activation of a lilr protein..
Icahn School Of Medicine At Mount Sinai

Composition comprising hmss/hmos and use thereof

The application relates to a method for the prophylaxis or treatment of non-infectious diarrhea in a human, the method comprising administering to the human an effective amount of one or more human milk oligosaccharides.. .
Glycom A/s

Detection of infectious prion protein by seeded conversion of recombinant prion protein

The present disclosure relates to methods and compositions for the detection of infectious proteins or prions in samples, including the diagnosis of prion related diseases. One embodiment is an ultrasensitive method for detecting prp-res (prpsc) that allows the use of recombinant prp-sen (rprp-sen) as a substrate for seeded polymerization.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Dendritic cell generator

Devices, systems, and methods can be used for the automated production of dendritic cells (dc) from dendritic cell progenitors, such as monocytes obtained from peripheral blood. The invention makes it possible to obtain sufficient quantities of a subject's own dc for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and/or treating cancer or infectious disease..
Northeastern University

Chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.

Novel epitope for switching to th17 cell and use thereof

The present invention relates to a novel epitope to convert t cell to type 17 helper t (th17) cell. Specifically, the present invention relates to an epitope constituting the 41st to 50th amino acids (seq id no.2) of extracellular domain (ecd) of activation-inducible tumor necrosis factor receptor (aitr), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting t cell to th17 cell and a method of conversion for the same, a pharmaceutical composition comprising the antibody for preventing or treating infectious disease, a method for treating infectious disease using the antibody, a composition comprising the antibody for enhancing immunity, and a method for enhancing immunity using the antibody..
Eutilex Co., Ltd.

Modular antigen transportation molecules and uses therof

The present invention relates to (isolated) recombinant proteins, also referred to as improved mat (imat) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at least one cysteine residue is substituted with a different amino acid residue. Such imat molecules are useful specifically as vaccines, e.g., for therapy and/or prevention of allergies and/or infectious diseases and/or prevention of transmission of infectious diseases in equines.
Boehringer Ingelheim Vetmedica Gmbh

Compositions and methods for treating diseases by inhibiting exosome release

A multipartite peptide that inhibits release of exosomes in a cell, comprising an n-terminal end and a c-terminal end and comprising at least one secretion modifying region (smr) peptide from hiv-1 nef and at least one clusterin (clu)-binding peptide (clu-bp). Pharmaceutical compositions comprising these peptides alone or in synergistic combinations with other active agents in methods for treating cancers and/or infectious diseases are further provided herein..
Morehouse School Of Medicine

Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases

The present invention relates to bicyclic tetrahydrothiazepine of formula (i), wherein r1 to r3, x1, x2 and r18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods..
Evotec Ag

Liquid or gel delivery devices

A delivery device is for intermittently delivering materials such as liquids or gels over a sustained period of time to a surface in a controlled way. The surface mountable delivery device is capable of delivering, an antimicrobial agent to protect surfaces from microbial contamination and/or to disinfect surfaces, e.g.
Surfaceskins Limited

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein.
Curevac Ag

Combination of vaccination and inhibition of the pd-1 pathway

The present invention relates to a vaccine/inhibitor combination comprising an rna vaccine comprising at least one rna comprising at least one open reading frame (orf) coding for at least one antigen and a composition comprising at least one pd-1 pathway inhibitor, preferably directed against pd-1 receptor or its ligands pd-l1 and pd-l2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination.
Curevac Ag

Combination of vaccination and inhibition of the pd-1 pathway

The present invention relates to a vaccine/inhibitor combination comprising an rna vaccine comprising at least one rna comprising at least one open reading frame (orf) coding for at least one antigen and a composition comprising at least one pd-1 pathway inhibitor, preferably directed against pd-1 receptor or its ligands pd-l1 and pd-l2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination.
Curevac Ag

Prostate biopsy needle

Present invention solved the problem of complications occurred during transrectal prostate biopsy, mostly infectious and bleeding complications. Thus, the prostate biopsy needle according to the invention comprising a cannula (1), a pointed stylet (2), which is mounted slidably in the cannula (1), handles (3a, 3b) for the biopsy gun, which are located on the back side of the needle.
Debn Sp.zo.o.

Device for measuring differences in conductivity

A device for measuring differences in conductivity that allows early detection of infectious/inflammatory periodental and/or apical diseases or in joint and/or muscle regions, before they can even be detected radiologically. The device has an electrical emitter in millivolts, with a given negative-peak square wave and a given frequency, both defined by a pulse width and interval between pulses, which, by means of two electrodes, one stationary and one movable, is able to produce a mild tingling sensation on the patient's skin immediately over the teeth apices or joint and/or muscle regions as well as dermatological, glandular and integumentary areas affected by inflammation and/or infection and display the intensity of the condition affecting the tissue to the professional on an illuminated scale display..
Dental Catch Iberica,s.l.

Growing anti-pathogen microbes found in raw seeds to sufficient numbers inside an organic mixture or culture medium so that the entire mixture could then be used as a type of all-natural infectious diseases immunotherapy

A product and method that uses the ideal raw, plant-based, nutrient-rich, organic mixture to act as the perfect culture medium which allows and encourages recently discovered, continuously evolving, and extremely small but very powerful anti-pathogen microbes found in raw seeds to rapidly grow and multiple and to sufficient numbers so that these microbes and the plant-based mixture that comprises them can then be used together as an effective type of all-natural infectious diseases immunotherapy.. .

Biometric disease growth prediction

Embodiments include methods, systems and computer program products for patterning and predicting the growth of infectious diseases through analysis of portable objects. Aspects include receiving biometric data from a plurality of nodes.
International Business Machines Corporation

Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof

The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mrna containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells..
Tapimmune Inc.

Methods of optimizing nucleotide sequences encoding engineered influenza proteins

The disclosure provides methods for generating an optimized nucleotide sequence encoding an engineered influenza structural protein and the optimized nucleotide sequences obtained therefrom. The optimized nucleotide sequences can be used in a reverse genetics system to facilitate the rescue of infectious influenza virus containing the engineered structural proteins and/or enhance viral titers.
Sanofi Pasteur, Inc.

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein.
Curevac Ag

Infectious plasmodium sporozoites grown in vitro

The application is directed to in vitro-reared plasmodium sporozoites of human host range wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same. Provided herein are in vitro-reared infectious plasmodium sporozoites (spz) of human host range, particularly p.
Sanaria Inc.

Extended protection protein vaccines against infectious agents

Protein-based vaccines against infectious agents, including malaria and zika virus, are described. The protein-based vaccines include an antigen domain and an immature dendritic cell targeting domain and are administered in combination with an adjuvant..
Cyvax, Inc.

Methods of obtaining mononuclear blood cells and uses thereof

Methods of obtaining mononuclear blood cells are provided. Also provided are methods of using the obtained cells for treating diseases such as cancer, infectious disease, autoimmune disease, allergy, and graft rejection..
Biolinerx Ltd.

Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta

This disclosure relates to compositions and conjugates comprising an interleukin, e.g., il-15 and a polypeptide that specifically binds tgf-beta. Typically the polypeptide that specifically binds tgf-beta is a type ii tgf-beta receptor.
Children's Healthcare Of Atlanta, Inc.

Compositions and methods for the treatment of infections and tumors

Pd-1 antagonists are disclosed that can be used to reduce the expression or activity of pd-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these pd-1 antagonists in conjunction with an antigen from the infectious agent or tumor.
President And Fellows Of Harvard College

Antibody molecules to pd-1 and uses thereof

Antibody molecules that specifically bind to pd-1 are disclosed. The anti-pd-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders..
President And Fellows Of Harvard College

Novel anti-infective compound

The invention relates to novel infective agents, the use thereof for the production of a pharmaceutical composition for the treatment and prophylaxes of a disease, preferably an infectious disease, a pharmaceutical composition comprising said compound, and to methods of producing said compounds. The invention further relates to a new probiotic configured for preventing or reducing the colonization by a pathogenic microorganism of an organ of a living being..
Eberhard Karls Universitaet Tuebingen

Compositions and methods for the treatment of inflammation and pain

The invention relates to the compounds of formula i, formula ii, formula iii, formula iv and formula v or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, formula ii, formula iii, formula iv or formula v and methods for the treatment of inflammation and pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection.
Cellix Bio Private Limited

System and sterilizing and/or deimmunizing an object

A system for sterilizing and/or deimmunizing an object includes a stationary chamber at ambient pressure is configured to store an object to be sterilized and/or deimmunized therein. A solvent delivery subsystem is coupled to the chamber and configured to apply a directed volume of a non-toxic aqueous solvent to coat and wet the object to optimally hydrate proteins of infectious agents and/or immunological agents in or on the object for proteolysis.
Oneighty°c Technologies Corporation

Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system

A method for stimulating or enhancing the immune system with a composition that includes a eurycoma longifolia aqueous extract. Also provided is a method for reducing the risk of infectious disease by administering the composition.
Biotropics Malaysia Berhad

Bacterial detection cartridge

Described herein are methods and apparatus for rapid detection of microorganisms in biological samples (e.g. Blood) for analysis to determine the presence or absence of infectious microorganisms in the samples.
Becton Dickinson And Company

Novel proteins specific for cd137

The present disclosure provides human lipocalin muteins that bind cd137 and can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure also concerns methods of making cd137 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins.
Pieris Pharmaceuticals Gmbh

Deuterated o-sulfated beta lactam hydroxamic acids and deuterated n-sulfated beta lactams

Provided herein are deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical compositions thereof.. .
Skyline Antiinfectives, Inc.

Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof

The present invention relates to infectious dna clones, infectious chimeric dna clones of porcine circovirus (pcv), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (pmws) caused by pcv2. The new chimeric infectious dna clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic pcv1 in which the immunogenic orf gene of the pathogenic pcv2 replaces a gene of the nonpathogenic pcv1, preferably in the same position.
Iowa State University Research Foundation, Inc.

Ipn virus genome mutations and codon interactions

The present invention relates generally to infectious pancreatic necrosis virus (ipnv) and specifically to further characterisation of the genetic stability of ipnv genome. More in particular, the invention relates to greater appreciation and understanding of the frequency of mutagenesis and codon interactions that influence the replication capabilities, virulence and immunogenicity of the virus.
Fvg Limited

Hepatocytes and hepatic non-parenchymal cells, and methods for preparation thereof

The present invention pertains to hepatocytes, liver progenitor cells, cholangiocytes, liver sinusoidal endothelial progenitor cells, liver sinusoidal endothelial cells, hepatic stellate progenitor cells, hepatic stellate cells, and liver cellular tissue models, as well as to methods for preparing these cells. The present invention also pertains to a cell fraction comprising liver progenitor cells, liver sinusoidal endothelial progenitor cells, or hepatic stellate progenitor cells.
The University Of Tokyo

Methods and compositions for the activation of gamma-delta t-cells

The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta t-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.. .
American Gene Technologies International Inc.

Methods and compositions for the activation of gamma-delta t-cells

The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta t-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.. .
American Gene Technologies International Inc.

Methods and compositions for the treatment of cancer or other diseases

The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function.
City Of Hope

Targeted nanocarriers for targeted drug delivery of gene therapeutics

A targeted nanocarriers also termed nanomedicines and methods of preferentially, or actively, targeting and delivering a tool for gene transfer or genome editing (i.e., a plasmid or a restriction enzyme such as a zinc finger nuclease, a crispr/cas system, or a talen) or a tool for gene silencing or post-transcriptional regulation of gene expression (i.e., a microrna, a sirna, a mrna, an antisense oligonucleotide, or a sense oligonucleotide) to a range of mammalian cell species. Cell specific targeting is achieved by using nanocarriers featuring suitable targeting anchors having a targeting moiety that can be a carbohydrate, an antibody or an antibody fragment, a non-antibody protein derivative, an aptamer, a lipoprotein or a fragment thereof, a peptidoglycan, a lipopolysaccharide or a fragment thereof, or a cpg dna.
Rodos Biotarget Gmbh

Novel compounds

Wherein r1 is n-c4-6alkyl or c1-2alkoxyc1-2alkyl-; r2 is hydrogen or methyl; each r3 is hydroxy, halo or n-c1-3alkyl; m is an integer having a value of 2 to 4; n is an integer having a value of 0 to 3; and p is an integer having a value of 0 to 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Metabolically programmed metal chelators and uses thereof

The present invention provides compounds of formula (i), which are “metabolically programmed” metal chelators, e.g., lipophilic, absorbable (e.g., orally absorbable), and effective metal chelators that are converted in vivo to their hydrophilic, nontoxic metabolites. The present invention also provides compounds of formula (ii), which are also “metabolically programmed” metal chelators.
University Of Florida Research Foundation, Incorporated

Re3cube S.r.l.

. .

. .

. .

. .

. .

. .

Methods of detecting mirna

Described are non-invasive methods of detecting in vivo cell death by measuring levels of ubiquitous and tissue specific mirna. The method can be applied for detection of pathologies caused or accompanied by cell death, as well as for diagnosis of infectious disease, cytotoxic effects induced by different chemical or physical factors, and the presence of specific fetal abnormalities..
Gensignia, Inc.

Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease

The invention provides a chimeric receptor comprising nkg2d, dap10 and cd3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of nk cells.
National University Of Singapore

Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease

The invention provides a chimeric receptor comprising nkg2d, dap10 and cd3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of nk cells.
National University Of Singapore

Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease

The invention provides a chimeric receptor comprising nkg2d, dap10 and cd3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of nk cells.
National University Of Singapore

Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease

The invention provides a chimeric receptor comprising nkg2d, dap10 and cd3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of nk cells.
National University Of Singapore

Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof

The present invention relates to methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof. The resulting products are useful in the treatment of proliferative diseases and infectious diseases..
Albany Molecular Research, Inc.

Salts and prodrugs of 1-methyl-d-tryptophan

Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.. .
Newlink Genetics, Corp.

Nanoparticle conjugates and uses thereof

The targeted delivery of therapeutic agents to specific cells remains a challenge in drug delivery. Provided herein are nanoparticle-targeting agent conjugates that can be used for the targeted delivery of therapeutic agents to certain cells and target tissues.
Massachusetts Institute Of Technology

Cell penetrating peptides and complexes comprising the same

The present invention provides a cell penetrating peptide derived from zebra, which is optionally linked to a cargo molecule, such as at least one antigen or antigenic epitope. The present invention also provides a complex comprising the cell penetrating peptide and the cargo molecule.
Amal Therapeutics Sa

Versatile influenza virus vaccine composition

The present invention relates to a versatile influenza virus vaccine composition using the ha2 helical domain of a hemagglutinin protein, which is an influenza surface protein, and to a pharmaceutical composition for preventing or treating influenza virus infectious diseases. The polypeptide expressed by seq id no: 3 and the polypeptide expressed by residues 379 to 474 of seq id no: 1 of the present invention can be mass-produced in e.
Korea Research Institute Of Bioscience And Biotechnology

A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist

The present invention provides a novel complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one tlr peptide agonist, wherein the components a)-c) are covalently linked. Moreover, the present invention also provides a nucleic acid encoding such a complex, wherein the complex is a peptide or a protein.
Amal Therapeutics Sa

Therapeutic ozone agent and treatment

The use of a medical therapeutic ozone agent in vivo to treat a variety of disorders including, but not limited to hypoxic conditions, autoimmune disease, fibrotic disease, inflammatory disease, neurodegenerative disease, infectious disease, lung disease, heart and vascular disease, metabolic disease, and cancer, wherein the therapeutic ozone agent is administered in a therapeutically effective amount, which can convert carbon monoxide to carbon dioxide, thereby treating or preventing the disease in a patient.. .

Remotely-controlled in-situ treatment of infectious healthcare waste produced by small-medium waste producers

The remote control centre is configured to receive and process data from the infectious healthcare waste collection and treatment devices and to monitor, control and report on the operation thereof based on the specific applications and/or users' needs.. .

Compositions comprising peroxyacid and methods for producing and using the same

The present invention provides methods for producing a non α-keto peracid that has lower toxicity and lower corrosivity. The present embodiments also provide methods and compositions for reducing microbes on a surface, methods, and compositions for preventing and reducing infectious vegetative bacteria on a substrate, and methods and compositions for treating a wound.
Armis Biopharma, Inc.

Predicting resistance to disease

The invention relates to a method of predicting resistance to infectious pancreatic necrosis in salmon, the method comprising determining the alleles present at a dna polymorphism in the salmon and predicting whether or not the salmon is resistant to infectious pancreatic necrosis based on the determination of the alleles. The invention also relates to a method of selecting a salmon for use as broodstock, wherein the salmon is selected based on the prediction by the first method that the salmon will have resistance to infectious pancreatic necrosis..
Aquagen As

Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the t cell immunoglobulin and mucin protein-3 (hm-3). The invention provides a tim-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide.
Anaptysbio, Inc.

Antibodies directed against lymphocyte activation gene 3 (lag-3)

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the lymphocyte activation gene-3 (lag-3). The invention provides a lag-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide.
Anaptysbio, Inc.

Substituted urea depsipeptide analogs as activators of the clpp endopeptidase

In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the clpp endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
St. Jude Children's Research Hospital

Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof

The present invention relates to a tenofovir monobenzyl ester phosphamide prodrug, preparation method and pharmaceutical use thereof. Specifically, the present invention relates to a compound of general formula (x), or isomer, pharmaceutically-acceptable salt, hydrate or solvate thereof, preparation method and use thereof in the preparation of drugs for treating viral infectious diseases, preferably aids infection, hepatitis b or diseases caused by hepatitis b virus..

Virus-like particle with efficient epitope display

The invention relates to a virus-like particle (vlp) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject.
University Of Copenhagen

Compositions and methods of use for (pro)renin receptor antagonists

Disclosed are methods of treating kidney disease, infectious or inflammatory diseases, acute kidney injury and hypertension by administering a (pro)renin receptor (prr) antagonist. In some instances the prr antagonist is a polypeptide.
University Of Utah Research Foundation

Use of antibiotics with specific therapeutic activities combined with the simultaneous use of lactobacilli and/or bifidobacteria with a non-transferable antibiotic resistance, having the same therapeutic indication

The present invention relates to the use of antibiotics with specific therapeutic activities combined with the simultaneous use of lactobacilli and/or bifidobacteria having a non-transferable antibiotic resistance and with the same therapeutic indication as said antibiotics. In particular, the present invention relates to a composition comprising or, alternatively, consisting of antibiotics suitable for the treatment of acute and chronic intestinal infections due to gram-positive and gram-negative bacteria; diarrheic syndromes; diarrhea due to an imbalance of the intestinal microflora such as for example, summer diarrhea, traveler's diarrhea and enterocolitis; pre- and postoperative prophylaxis of infectious complications in gastrointestinal surgery; gastrointestinal diseases such as irritable bowel syndrome (ibs), constipation, alterations of intestinal microflora; chronic inflammatory intestinal diseases (ibd) and inflammations due to helicobacter pylori; said antibiotics belonging to the rifamycin family, preferably rifaximin, being combined with specific strains of bacteria belonging to the species bifidobacterium longum having the same therapeutic indication as said antibiotics..
Probiotical S.p.a.

Modified gamma delta t cells and uses thereof

The present invention provides composition and methods for the treatment of cancer or infectious diseases in a human. The invention includes the generation and administration of gamma delta t cells that express chimeric antigen receptors (cars) comprising an antigen binding domain, a hinge domain, a transmembrane domain, a costimulatory signalling domain with the inclusion or not of a cd3 zeta signalling domain.
Tc Biopharm Ltd

Methods of detecting signatures of disease or conditions in bodily fluids

Methods and compositions for diagnosing the presence of a cancer cell in an individual are provided. Methods and compositions for identifying a tumor-specific signature in an individual having cancer are also provided.
President And Fellows Of Harvard College

Use of immunesuppressant receptor

Bir1 functions as an immunosuppressive receptor, and the antagonist of bir1 has immunopotentive activity, which is able to use for preventing and/or treating a cancer, an immunodeficiency disease or an infectious disease.. .

Ido inhibitors

Presently provided are ido inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (ido) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.. .
Newlink Genetics Corporation

Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumor immunity

Porous silicon (psi) microparticles (psm) are disclosed, which provide an important advance in the area of cancer immunotherapeutics and molecular nanomedicine. In particular, potent psm-based adjuvants are disclosed for dendritic cell-based vaccines compositions, and methods for their use in a variety of cancer immunotherapies.
The Methodist Hospital

6-amino-purin-8-one compounds

Wherein r1 is c1-6alkylamino, c1-6alkoxy, or c3-7cycloalkyloxy; m is an integer having a value of 3 to 6; n is an integer having a value of 0 to 4; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Methods of sterilization and treating infection using irreversible electroporation

A method for treating an infection using irreversible electroporation is presented. The method includes providing an ablation device that has at least one electrode and inserting the ablation device into a target tissue of a patient.
Angiodynamics, Inc.

Predicting resistance to disease

The invention relates to a method of predicting resistance to infectious pancreatic necrosis in salmon, the method comprising determining the alleles present at a dna polymorphism in the salmon and predicting whether or not the salmon is resistant to infectious pancreatic necrosis based on the determination of the alleles. The invention also relates to a method of selecting a salmon for use as broodstock, wherein the salmon is selected based on the prediction by the first method that the salmon will have resistance to infectious pancreatic necrosis..
Aquagen As

Anti-tyro3 antibodies and uses thereof

The present invention relates to antibodies, in particular human or humanized antibodies, that bind to the extracellular domain of human tyro3 receptor, in particular to the immunoglobulin-like domain ig-1, and reduce or inhibit the binding of human gas6 to said receptor. The invention also relates to the uses of these antibodies in the diagnosis, prevention or treatment of hyperproliferative or infectious diseases..
Institut Curie

Immune modulator for immunotherapy and vaccine formulation

A recombinant flagrp170 protein and pharmaceutical compositions comprising a flagrp170 protein and related molecules encoding same, and cells presenting such a protein are provided. The flagrp170 protein comprises an nf-κb-activating domain of flagellin and an atp-binding domain truncated grp170.
Health Research, Inc.

Auditable infectious and hazardous waste disposal

A system for auditable treatment and destruction of waste is provided that includes a computer server with a database connected to a network. Readers and sensors record the set of containers from inventory into a waste processing line via a belt conveyor running from an exterior of a sealed enclosure to a shredder.
Aemerge Llc

Live attenuated virus vaccines for la crosse virus and other bunyaviridae

The invention relates to vaccine compositions including cev serogroup immunogens, attenuated and inactivated viruses of the cev serogroup and chimeric bunyaviridae. Also disclosed are methods of treating or preventing cev serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a cev serogroup immunogen, methods for detecting la crosse virus (lacv) infection in a biological sample and infectious chimeric bunyaviridae..
The United States Of America, As Represented By The Secretary, Dept.of Health And Human Services

Diazabicyclooctane compounds

Or a stereoisomer, tautomer or pharmaceutically acceptable salt or ester thereof, wherein a, r1 and r2 are defined herein. Also described are pharmaceutically acceptable compositions of formula (ii) compounds as well as methods for utilizing the compounds of formula (ii) and the pharmaceutically acceptable compositions of formula (ii) compounds as antibacterial agents and β-lactamase inhibitors, useful in the treatment of infectious diseases..

Vaccine compositions and methods of use thereof

Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, sirna, rna or dna to papcs or mhc class ii positive cells (e.g. Tumor cells).
University Of Miami

Treatment of infectious diseases

Disclosed herein are methods for treating or preventing a disease comprising administering a pharmaceutical composition comprising a therapeutically-effective amount of nitazoxanide to a subject having the disease, wherein the disease is causally linked to infection by one or more pathogens selected from the group consisting of members of the genus ebolavirus, members of the genus marburgvirus, members of the species dengue virus, human immunodeficiency viruses 1 and 2, and members of the species mycobacterium tuberculosis.. .
Children's Medical Center Corporation

Antibodies directed against interleukin 36 receptor (il-36r)

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the interleukin 36 receptor (il-36r). The invention provides an il-36r-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide.
Anaptysbio, Inc.

Engineered opsonin for pathogen detection and treatment

The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (mbl), which is an abundant natural serum protein that is part of the innate immune system.
President And Fellows Of Harvard College

Targeted apheresis using binding agents or ligands immobilized on membranes

This invention teaches a method of targeted apheresis that can be used to treat a variety of different diseases including infectious diseases, autoimmune disorders, and reducing circulating biomarkers associated with certain disorders e.g. Pre-eclampsia.

Oral delivery system

The present invention provides a delivery system for the treatment and/or prevention of infectious pathological changes, including compositions comprising polyhexanide, various pharmaceutical formulations, and processes for using these formulations in oral treatment modalities.. .

Methods for improved in vitro - in vivo efficacy determination

The invention provides methods for determining and evaluating the in vitro-in vivo activity relationship of the efficacy of families of compounds for infectious diseases such as tuberculosis. The validity of the methods can be confirmed by evaluation of the compounds in animal models, for example, in murine models of tuberculosis.
Ovata B.v.

Anti-cd27 antibodies

The present invention relates to anti-cd27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.. .
Merck Sharp & Dohme B.v.

Antibody molecules to lag-3 and uses thereof

Antibody molecules that specifically bind to lag-3 are disclosed. The anti-lag-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders..
Immutep S.a.

Immunomodulators

The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company

Ebna1 inhibitors and their use

Pharmaceutical compositions of the invention comprise ebna1 inhibitors useful for the treatment of diseases caused by ebna1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise ebna1 inhibitors useful for the treatment of diseases caused by latent epstein-barr virus (ebv) infection.
The Wistar Institute Of Anatomy And Biology

Anti-human vista antibodies and use thereof

The invention provides antagonistic and agonistic anti-human vista antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block vista's suppressive effects on t cell immunity and thereby promote t cell immunity.
Janssen Pharmaceuticals, Inc.

Substituted urea depsipeptide analogs as activators of the clpp endopeptidase

In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators with the clpp endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of search in the particular art and is not intended to be limiting of the present invention..
St. Jude Children's Research Hospital

Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof

The present invention relates to a novel compound of 4′-thionucleoside, a preparation method therefor, a pharmaceutical composition comprising the same and an application thereof. Specifically, the present invention relates to a phosphamide derivative of 4′-thionucleoside, a preparation method therefor, a pharmaceutical composition comprising the same, a use thereof in the preparation of a medicine for preventing or treating abnormal cell proliferation diseases (for example, tumors or cancers and related diseases) or virus infectious diseases, and a method of using the same for preventing or treating abnormal cell proliferation diseases (for example, tumors or cancers and related diseases) or virus infectious diseases..
Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

Bacterial topoisomerase i inhibitors with antibacterial activity

The present invention provides compounds as bacterial topoisomerase inhibitors with antibacterial activity. The present invention also provides pharmaceutical compositions comprising at least one of the compounds and methods of using the compounds and pharmaceutical compositions as antibacterial agents for treating infectious diseases..
University Of Hawaii

Method for treating infectious diseases using emissive energy

The present invention relates to the treatment of infectious diseases, specifically by extracorporeally eradicating the pathogen. This invention comprises methods for the extracorporeal treatment of infectious diseases that will remove infectious pathogens (leukemia cells, bacteria, viruses, or fungi causing a septicemia, metastatic cancer cells, target protein, viruses, parasites, fungi and prions) in humans by targeting such pathogens with a laser or other high-energy source of emissive radiation.
Marv Enterprises, Llc

Pd-1 peptide inhibitors

This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (pd-1). These peptides block the interaction of pd-1 with its ligand pd-l1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis..
Leidos, Inc.

Daejeon University Industry-university Cooperation Foundation

. .

Ibv strains and uses thereof

The present invention relates to novel infectious bronchitis virus strains and the uses thereof. The invention particularly relates to an inactivated or attenuated ibv, as well as to vaccine compositions comprising the same and the uses thereof to vaccinate avians.
Biomune Company

Anti-tigit antibodies

The present invention relates to anti-tigit antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.. .
Merck Sharp & Dohme Corp.

Macrolides with modified desosamine sugars and uses thereof

Provided herein are macrolide compounds of formula (i) and (i-n) for the treatment of infectious diseases and inflammatory conditions. The 14-membered ketolides and 14-, 15-, and 16-membered azaketolides described herein comprise modified sugars which are desosamine or mycaminose analogs.
President And Fellows Of Harvard College

Immune checkpoint inhibitors, compositions and methods thereof

For formula (i) compounds r1, r2, x1, y1 and n are as defined in the specification. The inventive formula (i) compounds are inhibitors of the pd-1/pd-l1 protein/protein binding or functional interaction and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer and infectious diseases..

Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom

The present invention is directed to novel nucleotide and amino acid sequences of porcine epidemic diarrhea virus (“pedv”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine pedv genotypes and isolates.
Zoetis Services Llc

Composition for treatment or prevention of infectious inflammatory diseases, or composition for immune enhancement, comprising tryptophanyl-trna synthetase as an active ingredient

The composition of the present invention can be effectively used for preventing or treating diseases of humans and animals caused by infection from bacteria, viruses or fungi and the like by inhibiting infections such as bacterial, viral, and fungal infections at an early stage particularly through activating innate immune response.. .

Identification, monitoring and treatment of infectious disease and characterization of inflammatory conditions related to infectious disease using gene expression profiles

A method is provided in various embodiments for determining a profile data set for a subject with infectious disease or inflammatory conditions related to infectious disease based on a sample from the subject, wherein the sample provides a source of rnas. The method includes using amplification for measuring the amount of rna corresponding to at least 2 constituents from table 1.
Life Technologies Corporation

Raav vector compositions, methods for targeting vascular endothelial cells and use in treatment of type i diabetes

Disclosed are capsid-modified raav expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated raav vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian vascular system, and complications from type i diabetes.
University Of Florida Research Foundation, Inc.

Mzb1, a novel b cell factor, and uses thereof

The marginal zone (mz) and b1 subsets of b cells, which differ from conventional follicular (fo) b cells both developmentally and functionally, are involved in early responses to infectious pathogens and the production of self-reactive antibodies. A novel gene, mzb1, is expressed at high levels in mz and b1 b cells but at low level, if at all, in fo b cells.
Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v.

Compounds useful as immunomodulators

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use.
Bristol-myers Squibb Company

Methods and coupling an electromagnetic radiation conduction system into a catheter

Methods and apparatus for the inactivation of infectious agents in, on or around a catheter residing in a patient's body cavity. The method comprises a coupling adapter for facilitating the transmission of non-ultraviolet sterilizing electromagnetic radiation (emr) substantially axially along an optical element into the catheter body.

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein

The present application describes a coding nucleic acid sequence, particularly a messenger rna (mrna), comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g.
Curevac Ag

Lanthionine synthetase c-like 2-based therapeutics

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease..
Landos Biopharma, Inc.

Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin

A diagnostic method for the identification of a subject suffering from a primary non-infectious disease having an increased risk of an adverse outcome potentially being induced by the administration of an antibiotic to said subject comprising the determination of the level of procalcitonin (pct) or a fragment thereof or a precursor or fragment thereof having a length of at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk induced by the administration of an antibiotic, as well as a kit for performing the method and methods of treatment based thereon.. .
B.r.a.h.m.s Gmbh

Antibodies directed against programmed death-1 (pd-1)

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (pd-1) protein. The invention provides a pd-1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide.
Anaptysbio, Inc.

Bcr-complex-specific antibodies and methods of using same

This invention relates to chimeric and humanized antibodies that specifically bind the bcr complex, and particularly chimeric and humanized antibodies to the bcr complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.

Leukocyte esterase detection from throat swab

The present invention relates to the field of infectious diseases. The invention specifically relates to the diagnostic test for acute bacterial pharyngitis.

Method and system for tissue treatment with critical/supercritical carbon dioxide

Methods of decontaminating bone tissue and an apparatus or system for the same are provided. The methods can be multi-batch processes and include contacting the bone tissue having contaminants with carbon dioxide to decontaminate the bone tissue and to form carbon dioxide having contaminants.
Warsaw Orthopedic, Inc.

Immunomodulatory fusion proteins and uses thereof

The present disclosure relates to immunomodulatory fusion proteins containing an extracellular binding domain and an intracellular signaling domain, wherein binding of a target can generate a modulatory signal in a host cell, such as a t cell. The present disclosure also relates to uses of immune cells expressing such immunomodulatory fusion proteins to treat certain diseases, such as cancer or infectious disease..
Fred Hutchinson Cancer Research Center

System and inactivation of infectious pancreatic necrosis virus (ipnv) using medium pressure ultraviolet (uv) light

A method and a system is provided for inactivation of infectious pancreatic necrosis virus (ipnv) comprising illuminating a liquid containing ipnv with a lamp emitting a continuous broad band of ultraviolet (uv) light. The uv lamp may be “tuned” to optimize ipnv inactivation.
Atlantium Technologies Ltd

Methods and apparatus to inactivate infectious agents on a drainage catheter residing in a body cavity

Methods and apparatus for the inactivation of infectious agents in, on or around a catheter residing in a patient's body cavity. The method comprises a coupling adapter for facilitating the transmission of non-ultraviolet sterilizing electromagnetic radiation (emr) substantially axially along an optical element into the catheter body.

Vacuum assisted skin penetrating appliance with external interface

A system and method for a modular external interface for a skin penetrating appliance is provided. The modular device prevents internalization of bacteria, other infectious agents, or other unwanted materials from entering the access point for a catheter, steinman pin, kirschner wires, or other percutaneous instruments.
Viaderm, Llc

Glucocerebroside treatment of disease

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or t cell receptor ligand, preferably a glucosylceramide, to a mammalian subject.
Enzo Therapeutics, Inc.

Glucocerebroside treatment of liver disorders

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or t cell receptor ligand, preferably a glucosylceramide, to a mammalian subject.
Enzo Therapeutics, Inc.

Multiplex immuno screening assay

The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients.
Institut Pasteur

Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing

Methods are provided for predicting a subject's infection status using high-throughput t cell receptor sequencing to match the subject's tcr repertoire to a known set of disease-associated t cell receptor sequences. The methods of the present invention may be used to predict the status of several infectious agents in a single sample from a subject.
Fred Hutchinson Cancer Research Center

Capsid-modified raav vectors and methods of use

Disclosed are tyrosine-modified raav vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant raav vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene therapy, and large-scale production of raav vectors..
University Of Florida Research Foundation, Incorporated

Molecular antigen array

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array.
Kuros Biosciences Ag

Anti-pd-1 antibodies

The present invention relates to anti-pd-1 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease. These antibodies have cdrs as provided in the enclosed sequences.
Aduro Biotech Holdings, Europe B.v.

Icos binding proteins

The present invention relates to an icos binding protein or antigen binding portion thereof that is an agonist to human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell.
Centre National De La Recherche Scientifique (cnrs)

Immunotherapeutic vaccine and antibody combination therapy

The present invention relates to a combination product, composition(s) and kit of parts comprising at least (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s). The present invention also concerns a method for treating a proliferative or an infectious disease as well as a method for eliciting or stimulating and/or re-orienting an immune response, wherein said methods comprise administering to a subject in need thereof said combination product or said composition(s)..
Transgene Sa

Methods for preventing or treating infectious diseases caused by extracellular microorganisms, including antimicrobial-resistant strains thereof, using gallium compounds

The present invention relates to methods for preventing or treating infectious diseases caused by extracellular microorganisms, such as bacteria and fungi, by systemically administering to a patient a compound containing gallium. The extracellular microorganisms targeted by the present methods include methicillin-resistant staphylococcus aureus (mrsa), vancomycin-resistant enterococcus faecalis (vre), e.
Cahn School Of Medicine At Mount Sinai

Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies

The present invention relates generally to a medicinal solution, and more particularly to a medicinal solution which is to be continuously or pulse-delivered for the purpose of treating various ocular diseases, conditions, or maladies, such as keratoconus, infectious keratitis, severe inflammatory conditions, and ocular surface neoplasia. In particular, the medicinal solution comprises the combination of a medication for treating one of the aforenoted or similar diseases, conditions, or maladies, and an anesthetic for rendering the patient comfortable during the treatment procedure..

Polymer-based antimicrobial compositions and methods of use thereof

Provided is a polymer-based antimicrobial composition that is non-toxic, water soluble, and that mitigates the transmission of infectious diseases from surfaces. The composition comprises a cationic polymer, at least one adhesion promoter, optionally organic and/or inorganic particles that are photocatalytically active in visible light, and a carrier, in which the components of the composition are not covalently bound to one another.
Exion Labs Inc.

Conjugates of cell binding molecules with cytotoxic agents

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (i), wherein t, l, m, n, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, and r13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.. .
Beekenkamp Plants B.v.

University Of Washington Through Its Center For Commercialization

. .

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof

Hepatitis c virus replication at extrahepatic sites has been suggested; however, complete viral replication has only been confirmed in hepatocytes. Here we show that human adipogenic dlk-1+ stem cells (hadsc) freshly isolated from hcv-infected individuals contained viral transcripts, replication intermediates and viral antigens in vivo, and viral transcripts increased in supernatants upon prolonged ex vivo culture.
Frontier Bio-drug Development Limited

Method for preparing antigen-specific cytotoxic t-cells by using activated b-cells and use thereof

Disclosed in the present application are: a method for preparing in vitro/ex vivo antigen-specific cytotoxic t-cells by using b cells treated with biological response modifier; and a use thereof. The cytotoxic t-cells prepared by the method of the present application can be used advantageously for treating infectious disease and cancer and the like..
Seoul National University R&db Foundation

Chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.

Targeted conjugates encapsulated in particles and formulations thereof

Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided.
Tarveda Therapeutics, Inc.

Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells

Provided herein are methods of treating a hematological disorder, a solid tumor, or an infectious disease in a subject in need thereof using natural killer cells in combination with a second agent, or using natural killer cells with genetic modifications for target specificity and/or homing specificity.. .
Anthrogenesis Corporation

Novel multivalent nanoparticle-based vaccines

Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus.
The Usa, As Represented By The Secretary Department Of Health And Human Services

Information spread in social networks through scheduling seeding methods

A method for information spread in one or more social networks, the method may include receiving or generating social network information that represents members of the one or more social networks and links between the members; repeating, for each point in time out of multiple points in time, the steps of: determining, in response to budget constraints and current statuses of the members, and the current influence vectors of the members social circle, at least one target member that is non-infected during the point of time and should be infected before the next point in time, to provide an increase in the final number of infected members; wherein the statuses of the members comprises (i) infected and infectious, (ii) non-infected and (iii) infected and non-infectious; and sending, at a cost, the information to the at least one target member, before the next point in time.. .
Ramot At Tel-aviv University Ltd.

Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities

Disclosed herein are il-4 cytokine compositions with enhanced biological activity having increased selectivity for il-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (il-4) muteins.
The Board Of Trustees Of The Leland Stanford Junior University

Methods for making arrays for high throughput proteomics

Methods to obtain expression systems and proteins in a high-throughput protocol by utilizing mixtures of cells cultured from those transformed with a desired nucleotide sequence permit rapid production of protein for use in arrays to assess activity. In one embodiment, the proteins (or peptides) in the array are assessed for their immunological activity with regard to an infectious agent..
The Regents Of The University Of California

Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)

The present invention relates to novel compounds according to formula i that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis), lung diseases (e.g. Chronic obstructive pulmonary disease (copd) and lung interstitial diseases (e.g.

Enclosure for containment of material

An enclosure for containment and removal of hazardous material from objects is described, having a frame comprising a plurality of bars and a plurality of joints, each joint being releasably connectable to at least two bars, a flexible bag attachable to the frame, the bag being at least in part transparent, and comprising a resealable seam, and at least one adjusting device for tightening or loosening the bag on the frame. Usually, the enclosure, in use, is a negative pressure enclosure.
Claverend Innovations Limited

Methods and apparatus to deliver therapeutic, non-ultraviolet electromagnetic radiation to inactivate infectious agents and/or to enhance healthy cell growth via a catheter residing in a body cavity

Methods and apparatus provide therapeutic electromagnetic radiation (emr) for inactivating infectious agents in, on or around a catheter residing in a patient's body cavity and/or for enhancing healthy cell growth. The method comprises transmitting non-ultraviolet therapeutic emr substantially axially along an optical element in a lumen of the catheter body and/or the catheter body.

Synthetic nanoparticles for delivery of immunomodulatory compounds

The present disclosure provides a synthetic nanoparticle comprising a peptide nucleic acid (pna) oligomer conjugated to a lipid, wherein the pna oligomer noncovalently complexes with an immunomodulatory compound, thereby forming a nanoparticle. The nanoparticles are useful to elicit immune responses and can be used to treat a broad range of cancers and infectious diseases..
Massachusetts Institute Of Technology

Tryptophan is a pro-drug for infectious diseases and cancers

The innovation provides compositions and methods for treating infectious diseases and cancers, wherein said, in vitro, in higher active tdo (tryptophan 2,3-dioxygenase) sick cells that include cancer and infectious cells, tryptophan is capable of transferring into kynurenine derives to induce cells apoptosis; in vivo, tryptophan will turn into indican. Indican is capable of competing phosphorylation in the subject, competitively inhibiting process to form gtp, atp, dgtp, datp, that are essential for dna/rna synthesis; inhibiting host or invading gene amplification, or interfere with plk(polo like kinase) phosphorylation to trigger cell apoptosis.

Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for fcgammaractivating and fcgammarinhibiting

The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant fc region, wherein said variant fc region comprises at least one amino acid modification relative to a wild-type fc region, which variant fc region binds an fcγr that activates a cellular effector (“fcγractivating,” such as fcγriia or fcγriiia) and an fcγr that inhibits a cellular effector (“fcγrinhibiting,” such as fcγriia) with an altered ratio of affinities relative to the respective binding affinities of such fcγr for the fc region of the wild-type immunoglobulin. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by fcγr is desired (e.g., cancer, infectious disease) or an inhibited effector cell response mediated by fcγr is desired (e.g., inflammation, autoimmune disease)..
Macrogenics, Inc.

Modulation of antigen immunogenicity by deleting epitopes recognized by nkt cells

The invention describes a method and compounds for the prevention of immune responses towards allofactors, towards viral vectors used for gene therapy and gene vaccination, towards proteins to which subjects are naturally exposed, towards genetically-modified organisms and towards undesirable effects related to vaccine administration for allergic or infectious diseases.. .
Imnate Sarl

Enterococcus faecalis and/or enterococcus faecium antigen

The present invention generally relates to the field of detecting and preventing infectious diseases caused by enterococcus faecalis and/or enterococcus faecium. More specifically, the invention relates to an enterococcus faecalis and/or enterococcus faecium antigen which comprises at least one unit having the following general formula:.
Universitätsklinikum Freiburg

Inhibitors of trka kinase

The present invention is directed to the compounds of formula i which are inhibitors of tropomyosin-related kinase a (trka): formula (i) or steroisomers, tautomers or a pharmaceutically acceptable salts, metabolites, isotopes, solvates or prodrugs thereof, wherein, ra, rb, rc, rd, r1, r2, l and het-ar are as defined herein. These compounds can be used for the preventive and/or therapeutic treatment of diseases or disorders associated with abnormal activities of nerve growth factor (ngf) receptor trka such as pain, inflammation or an inflammatory diseases, cancer, atherosclerosis, restenosis, thrombosis, neurodegenerative diseases, erectile dysfunction (ed), skin disorders, autoimmune disease like multiple sclerosis, sjögren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination..
Gvk Biosciences Private Limited

Compounds, compositions and associated methods comprising 3-aryl quinolines

Compounds, compositions and methods useful for treating infectious diseases are provided. In particular, 3-aryl quinoline compounds, their synthesis, pharmaceutical compositions thereof and methods of treating infectious diseases such as malaria, are disclosed..
The United States Government As Represented By The Department Of Veterans Affairs

Sanitizing apparatus support

The present disclosure presents sanitization devices and methods. More particularly, the disclosure presents devices and methods that significantly reduce or eliminate the activity of germs, bacteria and/or other infectious microorganisms from a variety of objects.
Sanitizall Corp.

Adaptation of attenuated infectious bronchitis virus (ibv) to embryonic kidney cells and vaccine thereby produced

Disclosed are methods for preparing a vaccine against infection by infectious bronchitis virus (ibv). The methods typically include passing a heterogeneous attenuated population of ibv in chicken embryonic kidney cells, and optionally may include further passaging the heterogeneous attenuated population of ibv in embryonated chicken eggs (ece) in order to obtain passaged attenuated population of ibv.
Auburn University

Rna virus attenuation by alteration of mutational robustness and sequence space

The application generally relates to the attenuation of a rna virus or of a clone thereof and involves the alteration of sequence space, more particularly the reduction, of mutational robustness of said rna virus or clone. The means of the application are more particularly dedicated to the attenuation of an infectious rna virus or clone, for the production of immunogenic composition or vaccine.
Institut Pasteur

Lactic-acid-bacteria-containing composition, oral pharmaceutical composition for treating hpv infection and/or hpv-associated tumors, and mucosal immunity-inducing agent

A lactic acid bacterium-containing composition including a lactic acid bacterium having a human papillomavirus (hpv) e7 protein-derived polypeptide on a surface thereof, wherein the hpv e7 protein-derived polypeptide is included in an amount of 0.03 μg to 1.0 μg per 1×108 lactic acid bacteria; a therapeutic oral pharmaceutical composition for at least one of an hpv infectious disease and an hpv-associated tumor which includes the lactic acid bacterium-containing composition; and a mucosal immunity-inducing agent which includes the lactic acid bacterium-containing composition.. .
Japan Health Sciences Foundation

Use of prostacyclin antagonists for treating ocular surface nociception

The present invention relates generally to the use of compositions and methods for treating nociceptive events that occur on the ocular surface in association with dryness, injury, environmental pollutants, and infectious and non-infectious diseases. Specifically, the present invention is directed to the use of certain compounds for treating for treating ocular pain or ocular discomfort..
Jenivision Inc.

Non-streaking durable composition for cleaning and disinfecting hard surfaces

The present invention relates to quaternary ammonium disinfecting cleaning compositions comprising a quaternary ammonium compound, an alkyl a polyglycoside with a cmc greater than 1000 ppm and a chelant. Beneficially, the compositions provide residual sanitizing efficacy without diminished performance and without scale formation when diluted with hard water.
Ecolab Usa Inc.

Cyclic dinucleotides useful for the treatment of inter alia cancer

Or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases and conditions in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.

Oxathiazole thiazolium hsp 70 inhibitors

Provided herein are compounds of formula (i) which are, inter alia, useful allosteric inhibitors of hsp70. The compounds and methods provided are useful for the treatment of cancer, infectious and neurodegenerative diseases..
The Regents Of The University Of California

Targeted conjugates and particles and formulations thereof

Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution.
Tarveda Therapeutics, Inc.

Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease

Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases.
Riken

Stable formulations for the oral administration of amphotericin b and related methods

The present invention provides oral ampb and/or protease inhibitor formulations and their use to treat infectious disease, including hiv.. .
Ico Therapeutics Inc.

Therapeutic agent for keratoconjunctive disorders

The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a rarγ agonist as an active ingredient is provided.
Yamaguchi University

Methods for immunomodulation of cancer and infectious disease therapy

The present invention provides methods for modulating the immune response of a subject to a therapeutic agent, the method comprising administering an effective amount of a triphenylethylene (trip) compound with an effective amount of the therapeutic agent. In particular embodiments, the trip compound enhances the immune response of the subject to the therapeutic agent.
The Regents Of The University Of California

Method for identifying pathogens of bacterial infectious diseases by using bacteria-derived nanovesicles

The present invention relates to a method for predicting causative factors (bacteria) of serious bacterial infectious diseases in a clinical sample containing bacteria-derived nano-sized extracellular vesicles, that is, nanovesicles, through the analysis of the genes contained in the nanovesicles. According to the present invention, information on bacteria of serious bacterial infection can be provided, a causative factor of the bacterial infection can be predicted, and the resistance of the bacteria to antibiotics can be predicted..
Md Healthcare Inc.

Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions

The present disclosure provides novel macrocyclic peptides which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company

Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage

Disclosed herein are methods of diagnosing and treating infectious disease characterized by a pathology that involves hemorrhaging or pathological vascular leakage.. .
Duke University

Novel compound and antiviral agent containing same as active ingredient

An object of the invention is to provide a compound that can be utilized as an antiviral agent, in particular as an anti-rna viral agent, and especially as an anti-rs viral agent. The invention provides a compound indicated by formula (1), wherein r1 each independently represent hydrogen, halogen, hydroxyl, amino, carboxyl, c1-c6 alkyl, c1-c6 alkoxyl, c1-c6 halogenoalkyl, c1-c6 alkoxycarbonyl, c1-c6 alkylamino, c2-c5 alkenyl, c3-c6 cycloalkyl, or optionally substituted aryl; r2 each independently represent hydrogen, c1-c6 alkyl, c1-c6 halogenoalkyl, c2-c5 alkenyl, c3-c6 cycloalkyl, optionally substituted aryl or heterocyclic group; and one or more r1 may be present in the same ring, an isomer thereof, a pharmaceutically acceptable salt thereof, or a mixture of these.
National University Corporation Chiba University

Method for preparing a vaccine antigen, resulting vaccine antigen and uses

The present invention relates to a method for preparing a vaccine antigen, which includes a step of fragmenting a biological membrane associated with said vaccine antigen by treating said biological membrane with at least one calixarene of formula (ii): wherein: x is a —(ch2)-co2y group and y is an alkaline metal or one of the pharmaceutically acceptable salts thereof, wherein said resulting vaccine antigen also includes a fragment of the biological membrane associated with said antigen. The present invention also relates to a vaccine that can be produced by implementing the method, including a calixarene of formula (ii) in carrier format, with a quantity of 0.1 to 1,000 μg in the total weight of the vaccine.
Inserm

Recombinant aav production in mammalian cells

The present invention includes methods and compositions for the production of high titer recombinant adeno-associated virus (raav) in a variety of mammalian cells. The disclosed raav are useful in gene therapy applications.
University Of Florida Research Foundation Incorporated

Cd47 targeted therapies for the treatment of infectious disease

Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of cd47 on a infected cell to sirpα on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.. .
The Regents Of The University Of California

Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof

Novel synthetic biology-based adcc technologies are provided that enhance or enable adcc responses, for example, through a rationally-designed soluble universal adcc enhancer protein (suaep) where a high-affinity cd3-binding domain is fused to a high-affinity fc-binding domain. The suaep technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable..
1globe Biomedical Co., Ltd.

Infectious waste disposal

A system for treating infectious waste is provided that employs a medical waste handling and shredding sub-system that feeds partially processed waste to an oxidizer to eliminate potential airborne infectious waste prior to transforming the medical waste into useful co-products. Medical waste is transformed into value added products including hydrocarbon based gases, hydrocarbon-based liquids, carbonized material, and recovered precious metals and rare earth materials in a system having as its transformative element an anerobic, negative pressure, or carbonization system.
Aemerge Llc

Vaccine against infectious bronchitis virus

Embodiments of the present invention relate to an infectious bronchitis virus (ibv) and an immunogenic composition comprising an ibv, respectively, wherein the orf 3a and/or the orf 3b and/or the orf 5a and/or the orf 5b is inactivated. Furthermore, aspects of the present invention relate to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention.
Boehringer Ingelheim Vetmedica Gmbh

Peptidomimetic macrocycles and uses thereof

Provided herein are peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disorders, for example, for treatment of infectious diseases.. .
Aileron Therapeutics, Inc.

Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis

The present invention relates to compositions and methods for immunotherapy of a subject afflicted with diseases such as cancer, an infectious disease, or a neurodegenerative disease, which methods comprise administering to the subject a composition comprising a therapeutically effective amount of an anti-pd-l1 antibody or portion thereof that potentiates an endogenous immune response, either stimulating the activation of the endogenous response or inhibiting the suppression of the endogenous response.. .
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Compositions and methods related to viral vaccines

Provided herein are methods and compositions relating to infectious bursal disease virus (ibdv), and vaccines for treatment and prevention thereof.. .
Ohio State Innovation Foundation

Subunit immersion vaccines for fish

The present disclosure provides an immersion vaccine for fish comprising at least one isolated antigen, specifically a recombinant antigen, such as is f. Psychrophilum and/or infectious pancreatic necrosis virus (ipnv)..
Fvg Limited

Quaternary disinfectant composition with anionic scale inhibiting agent

The present invention relates to quaternary ammonium disinfecting cleaner compositions comprising a quaternary ammonium compound, an antimicrobial amine, and an anionic scale inhibitor. Beneficially, the compositions provide sanitizing efficacy without diminished performance and without scale formation when diluted with hard water.
Ecolab Usa Inc.

Devices, systems and methods to detect viable infectious agents in a fluid sample and susceptibility of infectious agents to anti-infectives

Various devices, systems and methods for detecting infectious agents or determining a susceptibility of an infectious agent to an anti-infective are described herein. One example method comprises introducing a fluid sample to a surface; exposing the surface to a solution; sampling the solution after exposing the solution to the surface; and detecting a change in an electrical characteristic of a sensing device exposed to the solution sampled corresponding to a presence of the infectious agent in the fluid sample..
Avails Medical, Inc.

Bandages for supplying ozone therapy

The present disclosure relates to a bandage wherein the bandage comprise of a first layer of protective covering, wherein the first layer is removable; a second layer of covering, wherein the second layer of covering is made of a cloth material; a third layer of covering, wherein the third layer is the top most layer of the bandage and together with the second layer forms a support pad; an injection, wherein the injection is present on the second layer of covering; a cylinder, wherein the cylinder is present in the support pad, wherein the bandage is used for delivering a medication to a localized area on a patient's body. The bandage is further used for delivering localized, painless ozone gas treatment to a patient suffering from infectious disease.
Umm-al-qura University

Multiplex immuno screening assay

The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients.
Institut Pasteur

Methods for making novel antigen binding domains

The present invention relates generally to the field of making novel antigen binding domains against infectious diseases. The present invention also relates to novel cars that utilize the novel antigen binding domains as an extracellular element.
Chimera Bioengineering, Inc.

Methods and compositions for the activation of gamma-delta t-cells

The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta t-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.. .
American Gene Technologies International Inc.

Nitroimidazole compound, preparation method therefor and use thereof in drug manufacturing

A nitroimidazole compound represented by general formula (i) or an optical isomer thereof or a pharmaceutically acceptable salt thereof, and a preparation method therefore, and use thereof in manufacturing drugs for the treating infectious diseases caused by mycobacterium tuberculosis. Specific groups in general formula (i) are as defined in the specification..
Shanghai Sun-sail Pharmaceutical Science & Technology Co., Ltd.

Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer

The present disclosure relates to benzamide compounds, prodrugs of the compounds, pharmaceutical compositions containing the compounds and/or the prodrugs and methods of using the compounds, prodrugs and pharmaceutical compositions in the treatment of diseases related to lipid metabolism including diabetes, non-alcholic fatty liver disease (nafld), non-alcholic steathohepatitis (nash), diseases caused by abnormal cell proliferation including cancer, psoriasis, and infectious diseases.. .

Microfluidic processing of leukocytes for molecular diagnostic testing

Described herein are microfluidic devices and methods that can greatly improve cell quality, streamline workflows, and lower costs. Applications include research and clinical diagnostics in cancer, infectious disease, and inflammatory disease, among other disease areas..

Dosage and administration of non-fucosylated anti-cd40 antibodies

This invention relates methods of using a non-fucosylated anti-cd40 antibody for treatment of cancer and chronic infectious diseases.. .
Seattle Genetics, Inc.

Convergent and enantioselective total synthesis of communesin analogs

Or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein r1-r8 and m, n, r, s, t, and u are as defined herein, is provided. Methods of making such compounds are also disclosed as are methods for the treatment of cancer, various infectious diseases, and abnormal cardiovascular function..

Method for making ice cream

A method for making ice cream including the following steps, performed in the following order: heating the side walls of the processing container to a preset preheating temperature; placing a basic ice cream mixture in the processing chamber after the step of heating the side walls of the processing container to a preset preheating temperature; deactivating any infectious agents which may be present in the basic mixture by activating the thermal treatment system in heating mode for a predetermined time in order to pasteurize the basic mixture inside the processing chamber; keeping the basic mixture, previously subjected to the thermal treatment inside the processing chamber, for a predetermined hold time.. .
Ali S.p.a. - Carpigiani Group

Recombinant viral vectors

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of aids. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention..
International Aids Vaccine Initiative

Compositions and methods for the treatment of mucositis

The invention relates to the compounds of formula i, formula ii, formula iii, formula iv, formula v, formula vi, formula vii and formula viii, or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, formula ii, formula iii, formula iv, formula v, formula vi, formula vii and formula viii, and methods for the treatment of mucositis may be formulated for oral, mouth wash, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection.
Cellix Bio Private Limited

Dosage regimen for pegylated interferon

A pegylated type i interferon for use in treating an infectious disease, cancer, or myeloproliferative disease in a subject in need thereof, wherein a 50 to 540 μg dose of the pegylated type i interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.. .
Pharmaessentia Corporation

Method of preparing mirabilitum praeparatum by pure strain fermentation and its applications

The present invention involves a method of preparing mirabilitum praeparatum by pure strain fermentation and its application in treating infectious and inflammatory diseases, as well as health products and cosmetics. The method involves blending the ripe fruit (watermelon) of citrullus lanatus (thumb.) matsumu.et nakai with mirabilite (na2so4.10h2o) according to a certain ratio as culture media and the pure strain penicillium rubens as zymocyte, and then fermenting under a certain temperature.

Phosphoramidite synthones for the synthesis of self-neutralizing oligonucleotide compounds

Compositions and compounds having nucleoside phosphoramidites, and methods of making the same are provided. The compounds can also have one or more amino groups that each can be positively charged.
Zata Pharmaceuticals, Inc.

Cai-based the localized treatment of uveitis

This invention relates to the treatment of uveitis, in particular posterior infectious uveitis. In specific embodiments, the invention provides for methods of treating uveitis and/or infectious uveitis comprising administration of a sustained-release system containing 5-amino-[4-(4-chlorobenzoyl)-3,5-dichlorobenzyl]-1,2,3-triazole-4-carboxamide) and optionally a glucocorticoid.
Gen Pharma Holdings, Llc

Icos binding proteins

The present invention relates to an icos binding protein or antigen binding portion thereof that is an agonist to human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell.

Compositions and methods related to viral vaccines

Provided herein are methods and compositions relating to infectious bursal disease virus (ibdv), and vaccines for treatment and prevention thereof.. .

Pyrazolo[1,5-a]pyridine compounds and use thereof

Disclosed in the disclosure are a pyrazolo[1,5-a]pyrideine compound with structural features as shown in formula (i) or a pharmaceutically acceptable salt, stereoisomer or prodrug molecule thereof and a use thereof. Such compounds have a good in vitro antituberculosis activity, and the minimal inhibitory concentration (mic) of the compounds is lower than 0.1 μg/ml and partially achieves 0.01 μg/ml, and have a very strong inhibiting effect on clinically selected multi-drug resistant tuberculosis (mdr-tb) strains.

Compositions and methods to prevent and treat biofilms

Compositions and methods to treat biofilms are disclosed based on the discovery of the role of the disaccharide trehalose in microbial biofilm development. In various embodiments to treat body-borne biofilms systemically and locally, the method includes administering trehalase, the enzyme which degrades trehalose, in combination with other saccharidases for an exposition time sufficient to adequately degrade the biofilm gel matrix at the site of the biofilm.

Targeted conjugates and particles and formulations thereof

Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution.

Monitoring method, information processing apparatus, information processing system, and non-transitory computer readable medium

The present invention provides a monitoring method for infectious diseases. The monitoring method includes: obtaining disease information from a plurality of medical facilities 131, 132, 133, and 134; determining the disease occurrence status for each medical facility based on the disease information and a first criterion related to the disease occurrence status at the medical facility; and generating first area alarm information related to the infectious disease status in a first zone based on the disease occurrence status in the medical facilities associated with the first zone divided by a first area division, and a second criterion related to the disease occurrence status in the first zone..
Sysmex Corporation

Compositions and methods of use for augmented immune response and cancer therapy

The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18), and compositions comprising one or more additional therapeutic agents. Provided compositions are useful in enhancing cd4+ and cd8+ t cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers.

Anti-tim-3 antibodies

Anti-tim-3 antibodies are disclosed, as well as pharmaceutical compositions comprising such antibodies, and uses and methods using the same, such as in the treatment of cancer or infectious disease or t-cell dysfunctional disorders. Bispecific antibodies against tim-3 and other targets are also disclosed, with a preferred embodiment of a bispecific antibody against tim-3 and cd3..
Agency For Science, Technology And Research

Cross reactive siglec antibodies

This invention relates to agents that bind multiple siglecs, including antibodies that neutralize the inhibitory activity of multiple siglec-7 and siglec-9 in lymphocytes. Such agents can be used for the treatment of cancers or infectious disease..
Innate Pharma

14-membered ketolides and methods of their preparation and use

Provided herein are methods of preparing new 14-membered ketolides via coupling of an eastern and western half moiety, followed by macro-cyclization, and optional functionalization. Intermediates in the synthesis of these ketolides including the eastern and western halves are also provided.
President And Fellows Of Harvard College

Methods of modulating immune system responses

Novel methods and uses for modulating immune responses are provided. The methods and uses involve the use of a tifa activator such heptose-1,7-5 bisphosphate or an analogue or derivative thereof.
The Governing Council Of The University Of Toronto

Combination therapy for the treatment of depression and other non-infectious diseases

The invention relates to methods, uses and compositions for treating non-infectious diseases with a therapeutically effective amount of a pharmaceutical composition comprising methylsulfonylmethane, glucosamine, l-glycine, and vitamin b12 (or a derivative of any one thereof).. .
Eaglepharma Pty Ltd

Formulations of methionine aminopeptidase inhibitors for treating infectious diseases

Provided herein are formulations and co-solvent formulations and methods for treating an infectious disease utilizing the same. The formulations and co-solvent formulations may comprise a hydroxyquinoline analog or its pharmaceutically acceptable salt, a solvent and at least two surfactants.
Texas Southern University

Dnazyme-nanoparticle conjugates and methods of use thereof

The present invention relates to dnazymes (also known as deoxyribozymes, dna enzymes, catalytic dna, or dz), which are conjugated to nanoparticles (np) to facilitate the detection of nucleic acids. One aspect of the invention relates to compounds comprising dnazymes conjugated to nanoparticles (dz-np), such as metallic or gold nanoparticles, and methods for their synthesis.

Deuterated o-sulfated beta lactam hydroxamic acids and deuterated n- sulfated beta lactams

Provided herein are deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical compositions thereof.. .

Bacterial topoisomerase inhibitors and use thereof

The present invention provides novel compounds as bacterial topoisomerase inhibitors with antibacterial activity. The present invention also provides pharmaceutical compositions comprising at least one of the compounds and methods of using the compounds and pharmaceutical compositions as antibacterial agents for treating infectious diseases..

Conjugates of cell binding molecules with cytotoxic agents

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (i), wherein t, l, m, n, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, and r13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.. .

Compositions and methods for treating an immunodeficiency virus infection

The present disclosure provides an interfering, conditionally replicating human immunodeficiency virus (hiv) construct; infectious particles comprising the constructs; and compositions comprising the construct or the particle. The constructs, particles, and compositions are useful in methods of reducing hiv viral load in an individual, which methods are also provided..

Methods for expanding t cell populations

The present invention provides methods for expanding populations of t cell. The present invention further provides pharmaceutical compositions comprising the expanded t cells, including, γδ t cells, and use thereof for treating infectious, autoimmune or malignant diseases..

Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide

A liquid formulation of (s)—n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.. .

Light-emitting versions of the monoclonal antibody to c3d (mab 3d29) for imaging

The presently disclosed subject matter provides compositions and kits comprising light-emitting versions of the monoclonal antibody to c3d (mab 3d29) for imaging and methods of use thereof for detecting infectious and inflammatory cells in vivo. The presently disclosed subject matter also provides methods for detecting and/or monitoring a mycobacterium tuberculosis (m.
The John Hopkins University

Activation of adaptive immune processes for the treatment of cancers and infectious diseases

Polypeptides, such as a multi-valent polypeptide designated svd2, useful in pharmaceutical compositions for stimulation of the adaptive arm of the immune system. Svd2 demonstrated in vivo activity in a syngeneic mouse model.
Susavion Biosciences, Inc.

Pyrazolopyrimidine compounds

Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Distinction of infectious virus based on molecular biomarker and neutralization of virus causing food poisoning

Discloses are a method for detecting norovirus using a norovirus animal model, a method for screening an antivial agent against norovirus, and a composition for neutralizing the infection with an enteric virus, containing concanavalin a as an active ingredient, so that the method for detecting norovirus can allow the distinction between infectious norovirus and non-infectious norovirus, and the composition can neutralize a virus causing food poisoning.. .
Korea Basic Science Institute

Method for rapidly determining effective sterilization , deimmunization, and/or disinfection

A method for rapidly determining effective sterilization, deimmunization, and/or disinfection of equipment and/or supplies by a device. The method includes providing a defined surrogate protein having a predetermined sequence representative of an infectious agent potentially contaminating the equipment and/or the supplies to be sterilized, deimmunized, and/or disinfected by the device.
Oneightyºc Technologies Corporation

Immunomodulators

The present disclosure provides novel macrocyclic peptides which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company

Immunomodulators

The present disclosure provides novel macrocyclic peptides which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company

Macrocyclic compounds as trk kinase inhibitors

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a, r3, r3a, and z are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .
Array Biopharma, Inc.

Antibodies to tigit

The invention provides monoclonal antibodies that specifically bind to tigit. The monoclonal antibodies have the capacity for substantial activation of t cells and natural killer cells by inhibiting binding of tigit to cd155.
Abmuno Therapeutics Llc

Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease

The invention relates to the field of cell therapy, particularly nk cell mediated therapy associated with antibodies. The present invention is directed to methods and compositions for increasing the efficiency of therapeutic natural killer cells (nk cells) and/or antibodies, wherein said methods or compositions comprise the use of pooled nk cells from umbilical cord blood units (ucbs), preferably alloreactive nk cells, in combination with a therapeutic antibody in order to enhance the efficiency of the treatment in human subjects, in particularly through an increase in antibody-dependent cell-mediated cytotoxicity (adcc) mechanism.
Emercell Sas

Multiplex immuno screening assay

The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological fluids of infected patients.
Institut Pasteur

Benzazepine sulfonamide compounds

Wherein r4 or r5 is —so2—nr7r8 and r1 to r8 and y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Method for analyzing health signal to respond to infectious disease and apparatus thereof

A method and an apparatus for analyzing a biosignal to respond to an infectious disease are provided. An analyzing method involves receiving biosignals of users of terminals and location information of the terminals, determining infectiousness of a condition of a user among the users by analyzing the location information and the biosignals, and transmitting feedback information regarding the infectiousness of the condition to one or more of the terminals..
Samsung Electronics Co., Ltd.

Production pluripotent stem cells having antigen-specific t cell receptor gene

(2) inducing t cell progenitors or mature t cells from the pluripotent stem cells provided in step (1). Pluripotent stem cells may preferably be ips cells.

Methionine analogs and methods of using same

Provided are methionine analogs which may be useful for inhibiting protein synthesis, inhibiting microbial growth and/or treating infectious diseases. In some instances, the analogs exhibit bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and/or antiviral properties.
Bioxiness Pharmaceuticals, Inc.

Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
Immunomedics, Inc.

Pharmaceutical formulations that form gel in situ

The present invention provides aqueous formulations containing an anti-infection agent, a biocompatible polysaccharide, an osmotic pressure regulator, a ph regulator, and water, wherein a gel containing the therapeutic agent is formed in situ upon instillation of the formulations onto the skin and a body cavity of a subject. The formulations of this invention are useful for treating infectious diseases of skin or a body cavity (e.g., eye, nose, or vagina) of a subject..
Iview Therapeutics, Inc.

A novel synergistic herbal formulation for degenerative disease cardiovascular diseases, autoimmune, inflammatory and metabolism disorder and the process of preparing the same

The present invention relates to a novel synergistic herbal formulation for degenerative disease, cardiovascular diseases, autoimmune, inflammatory and infectious diseases and metabolism disorder etc. Of man, animal and plants more particularly, the present invention relates to the herbal formulation for degenerative disease, cardiovascular diseases, autoimmune, inflammatory and infectious diseases etc which is prepared by using preparation of pongamia pinnata, dalbergia sissoo (shishu) and syzygium aromaticum (clove) which is used as directly and neuro pathways.

Prevention and treatment of microbial infections

Compositions for prevention and treatment of microbial infectious, such as microbial infections that comprise a biofilm, or a microbe that is capable of forming a biofilm are described. The compositions comprise an enzyme that is able to convert a substrate to release hydrogen peroxide and a substance that includes a substrate for the enzyme.
Matoke Holdings Limited

Cell growth method and pharmaceutical preparation for tissue repair and regeneration

The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum.
Sapporo Medical University

Drug delivery system and treating ocular diseases in animals

The present invention relates in general to the field of drug delivery systems for treating ocular diseases in animals, and more specifically, to a drug delivery system and method of treating infectious bovine keratoconjunctivitis (“ibk”) in cattle, commonly known as “pinkeye.” the drug delivery system and method may include a contact lens that has been infused with drugs for treating ibk, such as oxytetracycline, penicillin, streptomycin, tetracycline, gentamicin, cloxacillin or combinations thereof. The medicated contact lens may be placed in contact with the cornea and/or conjunctiva of the afflicted eye of the animal.

Methods and rapid detection of infectious microorganisms

An array of micro-chambers (220) with isfets (300) disposed therein for monitoring single cell activity in the microarray to determine the presence or absence of microorganisms in a sample (390).. .
Becton, Dickinson And Company

Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions

The present disclosure provides novel macrocyclic peptides which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company

Thienopyrroles as histone demethylase inhibitors

The present application relates to thienopyrrole derivatives, compounds of formulas (i) and (ia), wherein r, r1, r2 and r3 are as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy. The compounds of the application can be useful for inhibiting kdm1 and the prevention and/or treatment of cancer, infectious disease, or a disease characterized by aberration of cellular energy metabolism, e.g., obesity..
Istituto Europeo Di Oncologia S.r.l.

Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization

Presently provided are inhibitors of ido and tdo and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase and tryptophan 2,3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.. .
Newlink Genetics Corporation

Emulsified vaccine to obtain formulations of concentrated igy immunoglobulins; processes and uses for the same

The present invention relates to a therapy for treating or preventing several diseases in animals, based on the administration of a highly concentrated avian derived immunoglobulins formulation, obtained from the egg yolk from hens previously hiper-immunized with a vaccine formulation comprising infectious agents or toxins antigens, a light mineral oil and a particulate adjuvant.. .
Investiacion Aplicada, S.a. De C.v.

Protective covering for preexisting affixed medical equipment safety straps

A disposable cover used to protect preexisting affixed safety straps on medical equipment. The cover includes: 2 protective panels and hoop and loop fasteners on the inside for securing the cover to the preexisting affixed strap and hook and loop fasteners on the outer surface to allow the cover to secure to the opposing cover.

Method for the detection of antigen presentation

The present invention pertains to a method for detecting antigen presentation via antigen presenting molecules such as major histocompatibility complex (mhc) class i or ii. The invention deploys a first binding agent specific for the antigen epitope and a second binding agent specific for the antigen presenting molecule.
Deutsches Krebsforschungszentrum Stiftung Des öffentlichen Rechts

Immunomodulators

The present disclosure provides novel macrocyclic compounds which inhibit the pd-1/pd-l1 and pd-l1/cd80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.. .
Bristol-myers Squibb Company

Organic vaccination an alternative method to traditional preventative vaccination

The disclosed method provides an alternative approach of preventative vaccination which consists primarily of extracting and purifying monocytes, naive t and b lymphocytes from a patient and educating said lymphocytes against a pathogen in vitro until a population of antigen-specific memory lymphocytes are created with a memory against an infectious agent. Said memory lymphocytes are administered to a subject in a solution which consist primarily of blood plasma derived from said subject.

Protein-chaperoned t-cell vaccines

Protein antigens are provided. The protein antigens typically include a peptide antigen conjugated or fused to a chaperone protein to form a “chaperone-antigen” that increases lymph node uptake; improves an immune response; or a combination thereof relative to the peptide antigen alone.
Massachusetts Institute Of Technology

Devices and methods for using endovascular cooling to treat septic shock and other disorders

Apparatus, systems and methods for cooling or warming the temperature of all or a portion of the body of a human or animal subject to treat disorders including but not limited to sepsis, septic shock or other inflammatory or infectious conditions which can result in shock, hypoxia, ischemia and/or multiple organ failure in human or animal subjects.. .
Zoll Circulation, Inc.

Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases

The present invention pertains to the field of immunoterapy. More specifically, the present invention provides a method for differentiating myeloid-derived suppressor cells (mdsc) into non suppressive cells, by administering a compound blocking the interaction between sirpa and cd47 to a patient in need thereof in order to reduce mdsc-induced immunodepression and consequently allow appropriate immune responses in cancers, infectious diseases, vaccination, trauma, autoimmune diseases, chronic inflammatory diseases and transplantation..
Ose Immunotherapeutics

Antibody molecules to pd-1 and uses thereof

Antibody molecules that specifically bind to pd-1 are disclosed. The anti-pd-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders..
President And Fellows Of Harvard College

T-cell redirecting bispecific antibodies for treatment of disease

The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.
Ibc Pharmaceuticals, Inc.

Infectious hepatitis c viruses of genotype 3a and 4a and uses thereof

The present invention relates to molecular approaches to the production of nucleic acid sequences, which comprises the genome of infectious hepatitis c virus. In particular, the invention provides nucleic acid sequences which comprise the genomes of infectious hepatitis c viruses of either genotype 3a (strain s52) or genotype 4a (strain ed43).
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Anti-tim-3 antibodies

Anti-tim-3 antibodies are disclosed, as well as pharmaceutical compositions comprising such antibodies, and uses and methods using the same, such as in the treatment of cancer, infectious diseases, or t-cell dysfunctional disorders. Bispecific antibodies against tim-3 and other targets are also disclosed, with preferred embodiment of a bispecific antibody against tim-3 and cd3..
Agency For Science, Technology And Research

Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist

The present invention provides methods for enhancing the efficacy and/or safety of a vaccine. In certain embodiments, the invention provides methods to increase or potentiate the immune response to a vaccine in a subject in need thereof.
Regeneron Pharmaceuticals, Inc.

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

Novel compounds

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants..

Compositions for the treatment of peritonitis

The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and antimicrobial agents for the treatment, pre-emptive treatment or prevention of infectious peritonitis or intra-abdominal infection by intraperitoneal administration of the compositions.. .
Reponex Pharmaceuticals Aps

Immunological reagents

This disclosure relates to binding agents with specificity for programmed cell death 1 (pd-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (hiv)), cancer and/or autoimmunity.. .
Mabquest Sa

Gm-csf and il-4 conjugates, compositions, and methods related thereto

In certain embodiments, this disclosure relates to conjugates comprising a polypeptide of gm-csf and a polypeptide il-4. Typically, the gm-csf and il-4 are connected by a linker, e.g., polypeptide.
Children's Healthcare Of Atlanta, Inc.

Fluorinated benzofuranyl-pyrimidine derivatives containing a suflone group

The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyperproliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i).
Bayer Pharma Aktiengesellschaft

Method and removable catheter visual light therapeutic system

A medical device assembly is provided for removable insertion into a catheter with a lumen. The medical device assembly comprises an electromagnetic radiation (emr) source for providing non-ultraviolet, therapeutic emr having an intensity sufficient to inactivate one or more infectious agents and/or to stimulate healthy cell growth causing a healing effect, and a removable emr conduction system at least partially insertable into and removable from the lumen of the catheter.

An antagonistic pd-1 aptamer and its applications in cancer therapy related applications

Aptamers that bind to and antagonize pd-1 and uses thereof in promoting t cell proliferation, treating cancer or infectious diseases such as hiv infection.. .
National Taiwan University

Her2/neu-specific antibodies and methods of using same

This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.

Methods for treating thrombosis using chimeric and humanized anti-histone antibodies

The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.

Novel compounds for the treatment of infectious diseases

Wherein r1, r2, r3, r4, r5 and r6 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.. .

4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group

The present invention relates to 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (i) or (ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i) or (ia)..
Bayer Intellectual Property Gmbh

Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group

The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i)..
Bayer Pharma Aktiengesellschaft

Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors

Compounds of formula i: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where r1, r2, ra, rb, rc, rd, x, y, b, and ring c are as defined herein, and wherein the y—b moiety and the nh—c(═x)—nh moiety are in the trans configuration, are inhibitors of trka kinase and are useful in the treatment of diseases which can be treated with a trka kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .
Array Biopharma Inc.

Vaccine pharmaceutical composition for transdermal administration

The present invention provides a vaccine pharmaceutical composition for transdermal administration which is safe, usable as a prophylactic or therapeutic agent for cancer or infectious diseases, and capable of safely and effectively inducing a systemic immune response. It can be administered to a human or animal skin, the vaccine pharmaceutical composition including: a lipopolysaccharide or its salt derived from at least one gram-negative bacterium such as serratia, lelercia, rahnella, acidicaldus, acidiphilium, acidisphaera, acidocella, acidomonas, asaia, belnapia, craurococcus, gluconacetobacter, gluconobacter, kozakia, leahibacter, muricoccus, neoasaia, oleomonas, paracraurococcus, rhodopila, roseococcus, rubritepida, saccharibacter, stella, swaminathania, teichococcus, zavarzinia, pseudomonas, achromobacter, bacillus, methanoculleus, methanosarcina, clostridium, micrococcus, flavobacterium, pantoea, acetobacter, zymomonas, xanthomonas, and enterobacter, as an immunostimulant; and at least one antigen, the vaccine pharmaceutical composition having a mass ratio between the immunostimulant and the antigen, the total mass of the immunostimulant/the total mass of the antigen, of 0.002 to 500..
Nitto Denko Corporation

Coronavirus

The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject..
The Pirbright Institute

Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases

A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Llc

Devices, detecting viable infectious agents in a fluid sample using an electrolyte-insulator-semiconductor sensor

Various devices, systems and methods for detecting a susceptibility of an infectious agent to an anti-infective are described herein. A method comprises introducing a fluid sample to a first surface and a second surface; exposing the first surface to a first solution; exposing, the second surface to a second solution, wherein the second surface comprises an anti-infective; sampling the first solution after exposing the first solution to the first surface; sampling the second solution after exposing the second solution to the second surface; monitoring a first electrical characteristic of a first electrolyte-insulator-semiconductor (eis) sensor exposed to the first solution sampled; monitoring a second electrical characteristic of a second eis sensor exposed to the second solution sampled; and comparing the first electrical characteristic and the second electrical characteristic to assess the susceptibility of the infectious agent to the anti-infective..
Avails Medical, Inc.

Foxtail mosaic virus-based vectors for gene silencing and gene expression

The present invention provides plant virus vectors developed from the foxtail mosaic virus (fomv). The vectors include a nucleic acid sequence encoding an infectious foxtail mosaic virus (fomv) with a functional movement encoding sequence operably linked to one or more regulatory elements functional in a plant.
Iowa State University Research Foundation, Inc.

Immunostimulation by chemically modified rna

The present invention relates to an immunostimulating agent comprising at least one chemically modified rna. The invention furthermore relates to a vaccine which comprises at least one antigen in combination with the immunostimulating agent.
Curevac Ag

Antibody molecules to lag-3 and uses thereof

Antibody molecules that specifically bind to lag-3 are disclosed. The anti-lag-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders..
Immutep S.a.s.

Multispecific antigen binding proteins

Multimeric multispecific proteins formed from dimerization between ch1 and ck domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease..
Innate Pharma

Methods and systems for processing particles

Described herein are improved microfluidic devices and methods for processing cells that can improve cell quality, streamline workflows, and lower costs. Applications include research and clinical diagnostics in cancer, infectious disease, and inflammatory disease, among other disease areas..
University Of Maryland, Baltimore

Pegylated interferon-beta variant

The present invention provides a pegylated ifn-β variant and a composition for preventing or treating hyperproliferative diseases, inflammatory diseases, autoimmune diseases or viral infectious diseases, the composition comprising the pegylated ifn-β variant as an effective ingredient. The pegylated ifn-β variant of the present invention has an excellent anti-viral efficacy, immune regulatory function and anti-cell growth efficacy by virtue of better pharmacokinetic properties compared to native ifn-β and non-pegylated ifn-β variants, and therefore can be used usefully against various diseases.
Abion Inc.

Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same

Provided herein are compositions and methods for preparing intraarticular formulations comprising biocompatible pharmaceutical agents and use thereof in the treatment of diseases, such as degenerative bone diseases, including osteoarthritis of the knee, hip, or other joints, and similar chronic or acute destructive arthropathies resulting from autoimmune disorders or infectious disease.. .
Board Of Regents, The University Of Texas Sytem

Use of prostacyclin antagonists for treating ocular surface nociception

The present invention relates generally to the use of compositions and methods for treating nociceptive events that occur on the ocular surface in association with dryness, injury, environmental pollutants, and infectious and non-infectious diseases. Specifically, the present invention is directed to the use of certain compounds for treating for treating ocular pain or ocular discomfort..
Jenivision Inc.

Polycomplex gel for treating diseases of intestinal/digestive tract

The invention relates to the chemical and pharmaceutical industry and consists of a rectal gel substance for treating diseases of the intestinal/digestive tract, including nonspecific ulcerative colitis, crohn's disease, fistulae, etc., and also complications during the course of treatment of said diseases. The invention provides an antimicrobial and antiprotozoal effect and has good penetration capabilities.
Obschestvo S Ogranichennoi Otvetstvennostyu "gelizovit"

Proximity tracing methods and systems

Infection control methods and systems associate proximity-detection devices with people in a population, such as people in a hospital. Each proximity-detection device detects proximity events with other people.

Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases

A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.. .
Hycor Biomedical, Llc

Il-33 antagonists and uses thereof

The present invention provides interleukin-33 (il-33) antagonists comprising one or more il-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the il-33-binding domains can comprise an il-33-binding portion of an st2 protein and/or an extracellular portion of an il-1racp protein.

Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions

Described herein are dose escalation regimens for the administration of complexes comprising interleukin-15 (“il-15”) covalently or noncovalently bound to il-15 receptor alpha (“il-15rα”) to patients in order to enhance il-15-mediated immune function. In a specific aspect, the dose escalation regimens are useful in the prevention, treatment, and/or management of disorders in which enhancing il-15-mediated function is beneficial, such as cancer, infectious diseases, immunodeficienices and lymphopenia.
United States Departmen Of Health And Human Services

5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group

The present invention relates to 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i)..
Bayer Pharma Aktiengesellschaft

Agents for the treatment of retroviral infectious diseases

The invention relates to pyridine-3,5-bis-thiocyanates which are new active substances for the treatment and prevention of retroviral infections and secondary diseases thereof, in particular hiv infections and aids, from the group of deubiquitinase inhibitors. Administration of the compounds of the invention increases the immunogenicity of viral proteins and thus the antiviral response..
Immunologik Gmbh

Cultivation coffee tree by red ginseng powdered extract

A cultivation method of coffee tree by red ginseng powdered extract is provided, and particularly provided is a cultivation method of coffee tree through environment-friendly and rest (artificial dormant period) process using a red ginseng, and drink composition and food additive manufactured by the cultivation method of coffee tree by red ginseng, the method including: supplying red ginseng powdered extract aqueous solution to coffee seeds; and adjusting moisture of soil planted with coffee seeds. The cultivation method of coffee tree by red ginseng powdered extract has an advantageous effect in that coffee beans can be harvested having, as active ingredient, ginsenoside of high internal absorption rate capable of preventing occurrences of infectious diseases and pests by increasing immunity levels of coffee trees without using chemical fertilizers at all, and by enhancing germination percent of coffee seeds and coffee bean crops.

Psgl-1 modulators and uses thereof

The present invention relates to the seminal discovery that p-selectin glycoprotein ligand-1 (psgl-1) modulates the immune system and immune responses. Specifically, the present invention provides psgl-1 agonists and antagonists which increase the survival of multifunctional t cells and viral clearance.
Sanford-burnham Medical Research Institute

Anti-tigit antibodies

The present invention relates to anti-tigit antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.. .
Merck Sharp & Dohme Corp.

Antibody molecules to tim-3 and uses thereof

Antibody molecules that specifically bind to tim-3 are disclosed. The anti-tim-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders..
Children's Medical Center Corporation

Multispecific nkp46 binding proteins

Multispecific proteins that bind and specifically redirect nk cells to lyse a target cell of interest are provided without non-specific activation of nk cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease..
Innate Pharma

Single chain antigen recognizing constructs (scarcs) stabilized by the introduction of novel disulfide bonds

The present invention relates to a single chain antigen recognizing construct (scarc), which is composed of stabilized variable domains by the introduction of novel disulfide bonds, in order to prevent residual mis-pairing with endogenous arc chains. The invention further discloses a method for the design of a novel structurally stabilized scarc, the method being based on the visual inspection of the crystal structure of the underlying scarc and the selection of appropriate amino acid substitutions to generate a novel disulfide bond in the protein structure.
Universitätsmedizin Der Johannes Gutenberg-universität Mainz

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein.
Curevac Ag

Drug target and construct for japanese encephalitis virus infection

A group of mosquito-borne flaviviruses that cause fatal encephalitis in humans is among the most important of all emerging human pathogens of global significance. This group includes japanese encephalitis virus (jev), west nile virus, st.

Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector

Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject a robust immune response. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of a humoral immune response and/or cellular immune response is desired and beneficial..
Immune Design Corp.

Rapid detection of infectious agents

The invention generally relates to a method for detecting a target nucleic acid in a sample. This invention is useful for detecting bacterial or viral agents in a sample, and is able to detect nucleic acids from a broad variety of, e.g., bacteria, rather than only one or a few different bacteria at a time..
University Of Florida Research Foundation, Inc.

Perforin 2 defense against invasive and multidrug resistant pathogens

Perforin-2 (p2) is expressed by fibroblasts, microglia and macrophages and was found to be responsible for killing bacteria, for example, mycobacteria smegmatis, m. Avium, salmonellae, mrsa (drug resistant stapholococci), e.
University Of Miami

Antibody molecules to tim-3 and uses thereof

Antibody molecules that specifically bind to tim-3 are disclosed. The anti-tim-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders..
Children's Medical Center Corporation

Vacuum assisted percutaneous applicance

A luminal access device is provided that includes a luminal graft attached to a patient lumen. A percutaneous access device (pad) is coupled to the luminal graft and adapted to stabilize a conduit in fluid communication with the luminal graft and an external medical device.
Viaderm, Llc

New medical agents and uses thereof

The invention provides a novel compounds derived from cd154, but without the intracellular domain. Notably, the invention provides tmz-cd154 and a method to treat diseases in which the novel molecule tmz-cd154 is used.
Lokon Pharma Ab

Composition for preventing or treating staphylococcus aureus infection

A composition containing wall teichoic acid-attached peptidoglycan (wta-pgn) as an active ingredient, a method for preventing or treating staphylococcus aureus infectious diseases using the composition, and a method for preparing a soluble wta-pgn which can be used as an active ingredient in the composition are provided. The composition of the present invention can be effectively used for preventing or treating staphylococcus aureus infectious diseases by opsonophagocytosis due to antigen-antibody reaction and neutrophil-mediated phagocytosis due to t cell activation at the early stage of infection..
Pusan National University Industry-university Cooperation Foundation

Novel bacteriophage and composition comprising same

The present invention relates to a novel bacteriophage Φcj26 (kccm11464p) and a composition comprising the same as an active ingredient. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by salmonella by using the bacteriophage Φcj26 (kccm11464p) or the composition..
Cj Cheiljedang Corporation

Novel bacteriophage and composition comprising same

The present invention relates to a novel bacteriophage Φcj24 (kccm11462p) and a composition comprising the same as an active component. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by avian pathogenic e.
Cj Cheiljedang Corporation

Amide compounds, methods for preparation, and use thereof as agents for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases

The present invention relates to medicine and includes a method for preventing and treating diseases caused by rna- and dna-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula i or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by rna- and dna-containing viruses, said compositions comprising an effective amount of a compound of formula i or a pharmaceutically acceptable salt thereof.
Obschestvo S Ogranichennoi Otvetstvennostiyu "pharmenterprises"

Cd40 ligand fusion protein vaccine

Provided are methods of generating an immune response to any of various antigens including foreign antigens such as infectious agent antigens. In general, the method comprises administering an expression vector encoding a transcription unit encoding a secretable fusion protein, the fusion protein containing the foreign antigen and cd40 ligand and also administering the encoded fusion protein.
Microvax, Llc

Composition and reducing zoonotic infectious diseases

The presently disclosed subject matter relates to a composition and method of using the composition for oral delivery of a bioactive agent to a subject. More particularly, the presently disclosed subject matter relates to a composition comprising an effective amount of at least one bioacitve agent layered over a substrate and a method of reducing zoonotic infectious disease by administering the composition to a subject.
Us Biologic, Inc.

Mediated access to resources

Today's user is facing an ever increasing number of cyber threats from infectious software to scam artist phishing for their passwords and other personal information. Accordingly, a technique is provided to mediate a user's access to electronic resources, which can include malware and sites that trick the user into giving their password.
Mimecast North America, Inc.

Self assembling nucleic acid nanostructures

Stable self-assembling nucleic acid nanostructures comprising: —a plurality of oligonucleotides, —a plurality of g-quadruplex forming nucleic acids linked to the plurality of oligonucleotides, and —a plurality of g-quadruplex stabilizing domains linked to the g-quadruplex forming nucleic acids. The nucleic acid nanostructures are suitable for use as agonists or antagonists of nucleic acid interacting complexes, such as toll-like receptors; for inhibiting dna or rna expression; for stimulating or inhibiting an immune response; and for treating diseases such as cancer, infectious diseases, allergies and allergic diseases, and autoimmune diseases..
Exicure, Inc.

Icos binding proteins

The present invention relates to an icos binding protein or antigen binding portion thereof that is an agonist to human icos and does not induce complement, adcc, or cdc when placed in contact with a t cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said icos binding protein or antigen binding portion thereof. Further the icos binding proteins or antigen binding portions thereof of the present invention are capable of activating a t cell when placed in contact with said t cell; stimulating t cell proliferation when placed in contact with said t cell and/or inducing cytokine production when placed in contact with said t cell.
Glaxosmithkline Intellectual Property Development Limited

Bacterial phospholipase inhibitors as modulator of colonic bacterial flora

The present invention relates to the field of gastroenterology and, more particular, to the field of intestinal diseases. More specifically, it concerns uses and methods for the treatment of inflammatory bacterial diseases of the intestine.
Universitaetsklinikum Heidelberg

Live attenuated chimeric porcine circovirus vaccine

The present invention provides a novel chimeric porcine circovirus infectious dna clone and live attenuated chimeric virus with the pcv2, preferably of subtype pcv2b, capsid gene integrated into a non-pathogenic pcv1 virus genome. In a particular embodiment, the pcv2 capids gene is of subtype pcv2b, the predominant subtype circulating in pigs worldwide.
Virginia Tech Intellectual Properties, Inc.

Har-nds-derived stem cells, separating same, and use thereof

The present invention relates to hyaluronic acid-rich node and duct system (har-nds)-derived stem cells, a method for separating the same, and a use thereof and, more specifically, to node and ductal stem cells (ndscs), which are adult stem cells having an ability to differentiate into har-nds-derived neural cells, and hematopoietic stem cells having an ability to differentiate into blood cells. The present invention is capable of separating, from har-nds, adult stem cells ndscs and hematopoietic stem cells, which are not easy to obtain from bone marrow, peripheral blood and umbilical cord blood (cord blood), as an alternative source, and thus can be usefully used for treatment of brain diseases, neurological diseases, chronic infectious diseases, cancers, autoimmune diseases, organ regeneration treatments and various intractable diseases..
Eutilex Co., Ltd

Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same

There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as peg400 but essentially free of organic solvents and non-solubilized particles.
Platform Brightworks Two, Ltd.

Color-coded accessories indicating a medical diagnosis of a patient and enhancing patient safety

The present invention provides color-coded accessories such as wristbands, bibs, and other patient wearables, color-coded pillows and pillow cases, and a universal chart wherein the color code is associated with a specific medical diagnosis. These accessories alert healthcare providers to the medical diagnosis of the patient and enhance patient safety by reducing medical errors during administration of treatments and medicines to the patients.

Systems and methods for detecting infectious diseases

Systems, methods, and devices for detecting infections in a clinical sample are provided. Small-volume clinical samples obtained at a point-of-service (pos) location and may be tested at the pos location for multiple markers for multiple diseases, including upper and lower respiratory diseases.
Theranos, Inc.

Differential diagnostic method and kit for infectious and parasitic diseases, using flow cytometry

The present invention relates to a differential diagnostic method using flow cytometry, performed by means of differential fluorescent marking of biological agents, such as cells and pathogens of interest, with fluorescent substances. The diagnostic method generally consists in performing fluorescent marking of biological agents with gradual concentrations of fluorescent substances, and in analyzing the reactivity profile of igg1 to the biological agents.
Fundacao Oswaldo Cruz

Dnazyme-nanoparticle conjugates and methods of use thereof

The present invention relates to dnazymes (also known as deoxyribozymes, dna enzymes, catalytic dna, or dz), which are conjugated to nanoparticles (np) to facilitate the detection of nucleic acids. One aspect of the invention relates to compounds comprising dnazymes conjugated to nanoparticles (dz-np), such as metallic or gold nanoparticles, and methods for their synthesis.
The University Of Notre Dame

Immunological reagents

This disclosure relates to binding agents with specificity for programmed cell death 1 (pd-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (hiv)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“p2”) on pd-1 that is linked with a previously unidentified functional activity of pd-1 that is distinct from the interaction site involved with either the pd-l1 or pd-l2 ligands.
Mabquest Sa

Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them

The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound sirolimus or derivatives thereof, which is useful in the prophylaxis of organ rejection in patients receiving renal transplants, in the treatment of psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in birt-hogg-dubé syndrome, chronic erosive oral lichen planus, early stage cutaneous t-cell lymphoma, treatment of autoimmune active anterior uveitis, dry eye syndrome, age-related macular degeneration, diabetic macular edema, noninfectious uveitis, telangiectasia, inflammatory skin diseases (dermatitis, including psoriasis and lichen ruber planus), pachyonychia congenita and in the suppression of angiogenesis pathways. More specifically, the complex of the present invention possesses increased apparent solubility, permeability and enhanced biological performance including significantly improved exposure, earlier tmax, higher cmax and higher trough concentrations at 24 hours which will allow the reduction of the dose..
Druggability Technologies Ip Holdco Limited

Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity

The present application generally relates to the discovery that glycogen synthase kinase 3 (gsk-3) is an upstream signalling molecule that controls pd-1 transcription and tbet expression by immune cells and in particular t-cells. Based on this discovery, and in view of the known immunosuppressive effect of pd-1 on immunity and the promoting effect of tbet on t cell immunity, the present invention relates to the use of gsk-3 inhibitors to promote immunity, including cytotoxic t cell immunity in subjects in need thereof, especially subjects with chronic conditions wherein inhibiting pd-1 expression and/or blockade or tbet up-regulation is therapeutically desirable such as cancer and infectious conditions.

Intraocular delivery devices and methods therefor

Injection devices for delivering pharmaceutical compositions into the eye are described. Some devices include a resistance component for controllably deploying an injection needle through the eye wall.
Ocuject, Llc

Sterile site apparatus, system, and using the same

Apparatus, system, and methods are provided for reducing infectious agents at a sterile site by preventing infectious agents from coming into contact with the sterile site. A barrier is produced for infectious agents that may come in proximity or otherwise communicate with the site.
Armour Technologies, Inc.

Chemical gel to dissolve metal and hazardous medical sharps

This dissolvent is an inorganic compound of silica gel that is stabile and lasts for decades. Pleasant gold color, no evident odor or vapor, and it will not spill, or degrade over the decades, while awaiting use.

Human monoclonal antibodies to programmed death ligand 1 (pd-l1)

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to pd-l1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E.r. Squibb & Sons, L. L. C.

Novel compounds

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants..

Protein kinase inhibitors

The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the tec or src protein kinase families. The present invention also relates to processes for the preparation of these compounds, to the pharmaceutical composition comprising them, and to their use in the treatment of proliferative, inflammatory, infectious or autoimmune diseases, disorder or condition in which protein kinase activity is implicated..
Pharmascience Inc.

Conjugates of cell binding molecules with cytotoxic agents

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a formula (i), wherein t, l, m, n, y, r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r12, and r13 are defined herein, can be used for targeted treatment of cancer, autoimmune disease, and infectious disease.. .

Replication-competent vesicular stomatitis viruses

This document provides methods and materials related to vesicular stomatitis viruses. For example, replication-competent vesicular stomatitis viruses, nucleic acid molecules encoding replication-competent vesicular stomatitis viruses, methods for making replication-competent vesicular stomatitis viruses, and methods for using replication-competent vesicular stomatitis viruses to treat cancer or infectious diseases are provided..
Mayo Foundation For Medical Education And Research

Time zero classification of messages

Detecting infectious messages comprises performing an individual characteristic analysis of a message to determine whether the message is suspicious, determining whether a similar message has been noted previously in the event that the message is determined to be suspicious, classifying the message according to its individual characteristics and its similarity to the noted message in the event that a similar message has been noted previously.. .
Dell Software Inc.

Improved nanoparticle type oligonucleotide structure having high efficiency and preparing same

The present invention relates to an oligonucleotide structure and a method for preparing the same and, more particularly, to an oligonucleotide structure in which a polymer compound is linked to an oligonucleotide via a covalent bond to improve in vivo stability of the oligonucleotide and cellular delivery efficiency of the oligonucleotide; and to a method for preparing the same. The oligonucleotide structure is improved into a homogenous material, thereby solving the problem in material verification due to polydispersion characteristics occurring when a hydrophilic material linked to the oligonucleotide is a synthetic polymer; the oligonucleotide structure is easy to synthesize compared with the existing process; and the size of a double-stranded oligo rna structure can be accurately adjusted through the control of the repetition number of a hydrophilic material block, and thus, the gene expression regulation function of the oligonucleotide does not deteriorate through the synthesis of the optimized oligonucleotide structure, and the oligonucleotide can be delivered into cells at even a relatively low-concentration dosage.
Bioneer Corporation

Targeted conjugates and particles and formulations thereof

Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, comprising conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided.
Tarveda Therapeutics, Inc.

Enhanced immune response in cattle upon treatment with nitric oxide

The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the bovine species. The method is particularly effective for protecting a member of the bovine species from infectious disease and treating animals inflicted with infectious disease..
Bovicor Pharmatech Inc.

Methods for the treatment of infections and tumors

Pd-1 antagonists are disclosed that can be used to reduce the expression or activity of pd-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these pd-1 antagonists in conjunction with an antigen from the infectious agent or tumor.

Selective detection of haemophilus influenzae

A process for detecting haemophilus influenzae nucleic acid in a sample includes producing an amplification product by amplifying a haemophilus influenzae nucleotide sequence and measuring the amplification product to detect haemophilus influenzae in the sample. Some embodiments allow direct serotype determination in a single step assay.

Selective detection of haemophilus influenzae

A process for detecting haemophilus influenzae nucleic acid in a sample includes producing an amplification product by amplifying a haemophilus influenzae nucleotide sequence and measuring the amplification product to detect haemophilus influenzae in the sample. Some embodiments allow direct serotype determination in a single step assay.

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.

Dosage and administration of non-fucosylated anti-cd40 antibodies

This invention relates methods of using a non-fucosylated anti-cd40 antibody for treatment of cancer and chronic infectious diseases.. .
Seattle Genetics, Inc.

Ctla4 binders

The present invention provides molecules, such as isvds and nanobodies, that bind to ctla4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule.

Pd1/ctla4 binders

The present invention provides multispecific molecules, e.g., comprising more than one isvd or nanobody, that bind to pd1 and ctla4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule.

Pd1 and/or lag3 binders

The present invention provides molecules, such as isvds and nanobodies, that bind to pd1 and lag3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule.

Antibodies to il-15

The present invention relates to antibodies binding il-15, in particular humanized antibodies. In particular, the anti-il-15 antibodies according to the invention are able to neutralize il-15 activity and are useful in the prevention and/or treatment of an autoimmune disease and/or inflammatory disorder, a malignancy, transplant rejection, metabolic condition and/or an infectious disease caused by parasitic, viral or bacterial pathogens..
Calypso Biotech Sa

System for implanting, activating, and operating an implantable battery

Apparatus, systems, and methods for the treatment of bone, cartilage and other types of hard tissue. The treatments, which are suitable for extended treatment, include the treatment and prevention of pathologies through the controllable use of silver, iron, zinc, or magnesium ions.
Ortho-ion Ltd.

Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning

The invention provides isolated polynucleotide molecules that comprise a dna sequence encoding an infectious rna sequence encoding a genetically-modified north american prrs virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided..
Zoetis Services Llc

North american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof

The invention provides isolated polynucleotide molecules that comprise a dna sequence encoding an infectious rna sequence encoding a genetically-modified north american prrs virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided..
Zoetis Services Llc

Recombinant rsv reporter virus

An rsv reporter strain that can be used for high-throughput drug discovery is disclosed. Also disclosed is a recombinant rsv vector that contains an rsv genome encoding the disclosed rsv reporter strain operably linked to an expression control sequence.
Georgia State University And Research Foundation, Inc.

Prrs viruses, infectious clones, mutants thereof and methods of use

This disclosure provides isolated infectious polynucleotides, such as infectious clones, having a nucleotide sequence with identity to prrs viruses such as vr-2332, lelystad, or others, and optionally further including a deletion in a region of orf1 that encodes the nsp2 polypeptide.. .
Regents Of The University Minnesota

Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual

The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the human immunodeficiency viruses (hiv) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41..
Assistance Publique Hopitaux De Paris

Live attenuated classical swine fever vaccine based in genetic manipulation of a putative fusion peptide area in the virus structural glycoprotein e2

The role of a specific e2 region, 869ckwggnwtcv878, containing a putative fusion peptide (fp) sequence was evaluated. Fps critically contribute to the interaction between proteins and the membrane system of the host cell.
The United States Of America, As Represented By The Secretary Of Agriculture

Bacteriophage and antibacterial composition comprising the same

The present invention relates to a novel bacteriophage having a specific bactericidal activity against salmonella, a composition for the prevention or treatment of infectious diseases comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, an animal feed or drinking water comprising the bacteriophage as an active ingredient, and a sanitizer or cleaner comprising the bacteriophage as an active ingredient. The novel bacteriophage of the present invention has a specific bactericidal activity against salmonella choleraesuis, salmonella typhimurium, salmonella derby, salmonella infantis or salmonella newport with no influences on beneficial bacteria, as well as excellent acid- and heat-resistance and desiccation tolerance.
Cj Cheiljedang Corporation

Inhibitors of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity

The present invention relates to the general field of treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the treatment of immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity or an anti-inflammatory activity..
Universite D'aix-marseille

System and preventing transfer of infectious disease

A system and method to assist in the prevention of the transfer of infectious diseases. More particularly, a system and method that monitors and alerts caregivers to cleanse, sanitize, and/or wash their hands prior to engaging with other individuals in their care.

Methods and systems for rapid detection of microorganisms using infectious agents

Disclosed herein are methods and systems for rapid detection of microorganisms in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region.
Laboratory Corporation Of American Holdings

Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response

The present invention relates to the use of a recombinant lag-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer..
Immutep

A the treatment of glioblastoma with wharton jelly-mesenchymal stem cells (wj-msc) derived from human umbilical cord

The embodiments of the present invention provide a method for the treatment of glioblastoma using wharton jelly-mesenehmal stem cells (wj-msc) derived from human umbilical cord. The mesenchymal stem cells have potential to inhibit the glioblastoma cancer cells.

Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors

And salts thereof in which r1, r2, r3, r4, x, y and n have the meanings given in the specification, are inhibitors of trk kinases and are useful in the treatment of diseases which can be treated with a trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .

Lanthionine synthetase c-like 2-based therapeutics

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease..
Biotherapeutics, Inc.

Compositions comprising peroxyacid and methods for producing and using the same

The present invention provides methods for producing a non α-keto peracid that has lower toxicity and lower corrosivity. The present embodiments also provide methods and compositions for reducing microbes on a surface, methods, and compositions for preventing and reducing infectious vegetative bacteria on a substrate, and methods and compositions for treating a wound.
Chd Bioscience, Inc.

Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors

And salts thereof in which r1, r2, r3, r4, x, y and n have the meanings given in the specification, are inhibitors of trk kinases and are useful in the treatment of diseases which can be treated with a trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .

Macrocyclic compounds as trk kinase inhibitors

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a, r3, r3a, and z are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .
Array Biopharma, Inc.

Programmable universal cell receptors and using the same

The present invention provides programmable universal cell receptors (pucrs) comprising a catalytic antibody region, a transmembrane domain and a cytoplasmic domain. The pucrs disclosed herein may be conjugated to a specificity agent in order to program the receptor for specificity to any molecule of interest.
Sorrento Therapeutics, Inc.

Macrocyclic compounds as trk kinase inhibitors

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a, r3, r3a, and z are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .
Array Biopharma, Inc.

Regulation of cell membrane-mediated effects

The invention features methods of inhibiting cell membrane-mediated effects of infectious microorganisms and of a variety of factors on vertebrate cells with one or more of a family of glycerol-based compounds. The cell membrane-mediated effects are those resulting in, for example, infection of the vertebrate cells by relevant infectious microorganisms and inflammatory responses to infectious microorganisms or factors..
Hennipen Life Sciences, Llc

Methods for detecting a biomarker by alternating current electrokinetics

Methods are described for detecting pathogens, infectious diseases, and physiological conditions by quantifying change of impedance over time of when a biological sample is applied onto a lab-on-a-chip. The lab-on-a-chip utilizes alternating-current electrokinetic (acek) phenomena such that molecules move or are carried in an electric field generated by the application of an electrical signal of predetermined magnitude and frequency to an electrode array of the lab-on-a-chip..
University Of Tennessee Research Foundation

Nucleic acid amplification controls

The present invention discloses positive control material for nucleic acid amplification based detection of microorganisms in biological samples. The control material comprises purified microorganism that is rendered non-infectious but is amenable to nucleic acid amplification.
Zeptometrix Corporation

Double-stranded rna conjugates and their use

Double-stranded ribonucleic acids (dsrna) of at least 45 bp, preferably of at least 50 bp, which dsrna include at least one 5′-triphosphate group and further includes at least one chemical modification at a 5′ end, at a 3′ end and/or at a non-terminal nucleotide. The invention further provides pharmaceutical compositions containing such modified dsrnas, methods for their production, and to their use in medicine, in particular for immunostimulation and treatment as well as prevention of infectious, autoimmune, degenerative, cancer and tumor diseases..
Riboxx Gmbh

Personal vaccine and making

A method for the creation of a personalized vaccine. Multiple and varied antigens in conjunction with heat shock proteins (and other protein chaperones) are generated by ionized gas lysing coupled with the separation, concentration, and purification of these chaperone protein-antigen complexes (cpac) using insulator-dielectrophoresis (i-dep)-based devices.
Q21

Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease

The invention provides a chimeric receptor comprising nkg2d, dap10 and cd3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of nk cells.
National University Of Singapore

Macrocyclic compounds as trk kinase inhibitors

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a r3 and r3a are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.. .
Array Biopharma, Inc.

Compounds useful as immunomodulators

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use.
Bristol-myers Squibb Company

Personal vaccine and making

A method for the creation of a personalized vaccine. Multiple and varied antigens in conjunction with heat shock proteins (and other protein chaperones) are generated by ionized gas lysing coupled with the separation, concentration, and purification of these chaperone protein-antigen complexes (cpac) using insulator-dielectrophorsis (i-dep)-based devices.
Q21

Personal vaccine and making

A method for the creation of a personalized vaccine. Multiple and varied antigens in conjunction with heat shock proteins (and other protein chaperones) are generated by ionized gas lysing coupled with the separation, concentration, and purification of these chaperone protein-antigen complexes (cpac) using insulator-dielectrophorsis (i-dep)-based devices.
Q21

Personal vaccine and making

A method for the creation of a personalized vaccine. Multiple and varied antigens in conjunction with heat shock proteins (and other protein chaperones) are generated by ionized gas lysing coupled with the separation, concentration, and purification of these chaperone protein-antigen complexes (cpac) using insulator-dielectrophorsis (i-dep)-based devices.
Q21

Assays for determining the effect of an immune cell on a cell from an infectious or neoplastic disease

An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. Also provided is an in vitro assay for determining the effect of an activated cd8+ t-cell on a sensitized melanoma cell.
The Trustees Of Columbia University In The City Of New York

Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality

The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (hsp) preparation or an α-2-macroglobulin (α2m) preparation with a non-vaccine treatment modality. In particular, an hsp preparation or an α2m preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases.
University Of Connecticut Health Center

Pharmaceutical compositions comprising danirixin for treating infectious diseases

Provided are compounds and pharmaceutically acceptable salts thereof, and combinations of compounds, their pharmaceutical compositions, their methods of preparation, and methods for their use in treating or preventing infectious disease.. .
Glaxosmithkline Intellectual Property (no. 2) Limited

Intraocular delivery devices and methods therefor

Injection devices for delivering pharmaceutical compositions into the eye are described. Some devices include a resistance component for controllably deploying an injection needle through the eye wall.
Ocuject, Llc

Ibv strains and uses thereof

The present invention relates to novel infectious bronchitis virus strains and the uses thereof. The invention particularly relates to an inactivated or attenuated ibv, as well as to vaccine compositions comprising the same and the uses thereof to vaccinate avians.
Biomune Company

Targeted conjugates and particles and formulations thereof

Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution.
Tarveda Therapeutics, Inc.

Replication-competent vsv-hiv env vaccines

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of aids. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention..
International Aids Vaccine Initiative

Vaccination with immuno-isolated cells producing an immunomodulator

Provided herein are vaccine compositions containing at least one retrievable biocompatible macrocapsule containing immuno-isolated allogeneic cells that secrete an immunomodulator such as gm-csf (granulocyte-macrophage colony stimulating factor) and an antigenic component such as autologous tumor cells or infectious agents. Also provided are kits and pharmaceutical compositions containing the vaccine compositions as well as methods of use thereof for therapeutic or preventative vaccination against tumors or infectious agents..
Maxivax Sa

Novel tlr4 inhibitors for the treatment of human infectious and inflammatory disorders

The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have tlr4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Monoclonal antibodies to programmed death 1 (pd-1)

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Ono Pharmaceutical Co., Ltd.

Inhibitors of lpxc

Provided herein, inter alia, are compounds and methods for treating infectious diseases. The compounds provided herein are, inter alia, useful for the treatment of bacterial infections.
The Regents Of The University Of California

Modular antigen transportation molecules and uses thereof in animals

The present invention relates to (isolated) recombinant proteins, also referred to as improved mat (imat) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at least one cysteine residue is substituted with a different amino acid residue. Such imat molecules are useful specifically as vaccines, e.g.
Boehringer Ingelheim Vetmedica Gmbh

Cold-adapted-viral-attenuation (cava) and novel attenuated poliovirus strains

A poliovirus (pv) strain was attenuated by a novel method of cold-adapted-viral-attenuation (cava). The resulting recombinant attenuated pv, cava-pv, shows wild-type replication at 30° c., but no substantial replication at 37° c.
Crucell Holland B.v.

Vaccination with immuno-isolated cells producing an immunomodulator

Provided herein are vaccine compositions containing at least one retrievable biocompatible macrocapsule containing immuno-isolated allogeneic cells that secrete an immunomodulator such as gm-c sf (granulocyte-macrophage colony stimulating factor) and an antigenic component such as autologous tumor cells or infectious agents. Also provided are kits and pharmaceutical compositions containing the vaccine compositions as well as methods of use thereof for therapeutic or preventative vaccination against tumors or infectious agents..
Maxivax Sa

1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor

Provided is compound (i) or a pharmaceutically acceptable salt thereof, which is an inhibitor of trka kinase and is useful in the treatment of diseases which can be treated with a trka kinase inhibitor such as pain, cancer, inflammation and inflammatory diseases, neurodegenerative diseases, certain infectious diseases, sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, diseases related to an imbalance of the regulation of bone remodeling, and diseases resulting from connective tissue growth factor aberrant signaling.. .
Array Biopharma Inc.

Treatment of inflammatory and infectious skin disorders

Disclosed herein is a composition comprising of resveratrol and/or derivatives thereof and/or functionally related compounds and benzoyl peroxide and/or derivatives thereof and/or functionally related compounds for the treatment of acne and other inflammatory or infectious skin disorders. Also disclosed are methods of treating acne and other inflammatory and infectious skin disorders using the compositions described herein..
The Regents Of The University Of California

Novel compounds

Wherein r1 is n-c4-6alkyl or c1-2alkoxyc1-2alkyl-; r2 is hydrogen or methyl; each r3 is hydroxy, halo or n-c1-3alkyl; m is an integer having a value of 2 to 4; n is an integer having a value of 0 to 3; and p is an integer having a value of 0 to 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Treatment of skin and soft tissue infection with nitric oxide

The present invention generally relates to compositions and methods for treatment of skin and/or other soft tissues that are infected with bacteria such as staphylococcus aureus, and/or other infectious organisms. In some cases, the composition may include nitric oxide.
Transdermal Biotechnology, Inc.

Melatonin and its use in preventing postoperative complications

The invention relates to the use of melatonin, either alone or in combination with at least one compound selected from the group consisting of l-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof, for the manufacture of a medicament for the therapeutic treatment, prophylactic treatment and/or prevention of postoperative infectious and/or non-infections complications induced by surgical interventions wherein the infectious complications may be pneumonia, wound infection (wound dehiscence), intra-abdominal abscess, and urinary tract infections (uti) or wherein the non-infectious complication may be anastomotic leak, a pharmaceutical formulation comprising melatonin and at least one compound selected from the group consisting of l-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof and a method for the therapeutic and/or prophylactic treatment of postoperative infectious and/or non-infectious complications induced by surgical interventions.. .
Nutri-fit Gmbh & Co. Kg

Female urinary barrier system

A female urinary barrier system product that includes an exterior vaginal attachment pad for providing a female-user with means to prevent the spread of infectious diseases into their vaginal opening and urinary tract. The product provides a female-user a hand depressible attachment pad useful for enclosing/covering the vagina prior to a bowel movement or just prior to wiping.

Frontier Science Corporation

. .

Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples

The invention is directed to compositions and methods for rapidly detecting, amplifying, and quantitating one or more pathogen-specific nucleic acids in a biological sample, and in particular, samples obtained from patients with sepsis. The invention also provides diagnostic kits containing specific amplification primers, and labeled detection probes that specifically bind to the amplification products obtained therefrom.
Longhorn Vaccines And Diagnostics, Llc

Methods for diagnosing infectious diseases using adsorption media

The present invention provides an in vitro method for concentrating infectious pathogens found in a biological sample obtained from an individual who is suspected of being infected with the pathogens. Provided herein is also an in vitro method for reducing or eliminating blood cells from a sample obtained from an individual suspected to being infected with an infectious pathogen.
Exthera Medical Corporation

Pooled nk cells from ombilical cord blood and their uses for the treatment of cancer and chronic infectious disease

The invention relates to the field of cell therapy, particularly nk cell mediated therapy. The present invention relates to a method of producing an ex vivo population of cells, preferably nk cells, from at least two umbilical cord blood units (ucb units), or fraction thereof containing said cells, by pooling said at least two ucb units to produce said population of cells.
Institut National De La Sante Et De Recherche Medicale (inserm)

A chimeric peptide that interacts with cell membrane gangliosides

The invention relates to a chimeric peptide displaying the ganglioside-binding properties of both α-synuclein and β-amyloid peptide. Such peptide is useful in preventing or treating any condition which involves gangliosides as cell surface receptor sites, including neurodegenerative disorders, infectious diseases, or tumors..
Universite D'aix-marseille

Antimicrobial peptides

A novel antimicrobial peptide includes at least eight successive amino acids, the peptide exhibiting a sequence having the following formula: ter1-x1—b1—x2—b2—x3—z1—z2—x4-ter2. The peptide can moreover also have modified termini.
Robert Bosch Gesellschaft FÜr Medizinische Forschung Mbh

Suprametallogels and uses thereof

The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., pd(ii)-, ni(ii)-, or fe(ii)-ligand of formula (a)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers y.
Massachusetts Institute Of Technology

Composition for treating hbv infection

The present invention provides a composition comprising hepatitis b virus (hbv) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such hbv component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors.
Transgene S.a.

Toll-like receptor 2 agonists and vaccines and uses thereof

The present invention relates to toll-like receptor 2 (tlr2) agonists, in particular, to tlr2-activating lipoproteins, and more particularly to tlr2-activating lipopeptides derived from the bacteria bordetella pertussis. The invention further extends to the use of said tlr2-activating lipoproteins as a therapeutic or as part of a vaccine composition in the treatment and prevention of infectious diseases, cancer or allergic diseases..
The Provost, Fellows, Foundation Scholars & The Other Members Of Board, Of The College Of The Holy

Multivalent vlp conjugates

The invention is directed to vaccines comprising capsular polysaccharides conjugated to one or more components of virus like particles (vlp), and methods for the administration of and methods for the manufacture of vaccines of the invention. Preferably vaccines of the invention generate a therapeutically effective response in an individual in need thereof to multiple strains and/or serotypes of the same or of different infectious agents.
Inventprise, Llc

Methionine aminopeptidase inhibitors for treating infectious diseases

The present invention relates to methods for treating an infectious disease in a subject in need thereof via administration of a therapeutically effective amount of compounds described herein. The methods may utilize particular compounds, for example, a quinoline, a hydrazone, a quinone, or a pyrimidine derivative thereof or a pharmaceutical salt thereof..
Texas Southern University

Methionine aminopeptidase inhibitors for treating infectious diseases

The present invention relates to methods for treating an infectious disease in a subject in need thereof via administration of a therapeutically effective amount of compounds described herein. The methods may utilize particular compounds, for example, a quinoline, a hydrazone, a quinone, or a pyrimidine derivative thereof or a pharmaceutical salt thereof..
The Board Of Regents Of The University Of Texas System

Methionine aminopeptidase inhibitors for treating infectious diseases

The present invention relates to methods for treating an infectious disease in a subject in need thereof via administration of a therapeutically effective amount of compounds described herein. The methods may utilize particular compounds, for example, a quinoline, a hydrazone, a quinone, or a pyrimidine derivative thereof or a pharmaceutical salt thereof..
The Board Of Regents Of The University Of Texas System

Therapeutic agent for keratoconjunctive disorders

The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a rarγ agonist as an active ingredient is provided.
Yamaguchi University

Immunoassay test device with two fluid flow paths for detection and differentiation of two or more analytes

A device for determining presence or absence of infection due to an infectious agent is described. The device comprises a sample receiving zone configured to receive a liquid sample from a subject suspected of having an infection due to an infectious agent, the sample receiving zone positioned to distribute the sample along a first fluid flow path to a first label zone and along a second fluid flow path to a second label zone.
Quidel Corporation

Devices, detecting viable infectious agents in a fluid sample

Various devices, systems and methods for detecting a susceptibility of an infectious agent to an anti-infective are described herein. A method comprises introducing a fluid sample to a first surface and a second surface; exposing the first surface to a first solution; exposing the second surface to a second solution, wherein the second surface comprises an anti-infective; sampling the first solution after exposing the first solution to the first surface; sampling the second solution after exposing the second solution to the second surface; monitoring a first electrical characteristic of a first sensor exposed to the first solution sampled; monitoring a second electrical characteristic of a second sensor exposed to the second solution sampled; and comparing the first electrical characteristic and the second electrical characteristic to assess the susceptibility of the infectious agent to the anti-infective..
Esense, Llc

Devices, detecting viable infectious agents in a fluid sample

Various devices, systems and methods for detecting a susceptibility of an infectious agent to an anti-infective are described herein. A method comprises introducing a fluid sample to a first surface and a second surface; exposing the first surface to a first solution; exposing the second surface to a second solution, wherein the second surface comprises an anti-infective; sampling the first solution after exposing the first solution to the first surface; sampling the second solution after exposing the second solution to the second surface; monitoring a first electrical characteristic of a first sensor exposed to the first solution sampled; monitoring a second electrical characteristic of a second sensor exposed to the second solution sampled; and comparing the first electrical characteristic and the second electrical characteristic to assess the susceptibility of the infectious agent to the anti-infective..
Esense, Llc

Generation of infectious influenza viruses from virus-like particles

Compositions and methods to prepare influenza virus-like particles (vlps) are provided.. .

Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon

Wherein r1 is hydrogen, methyl or —(ch2)2or3, r2 is methyl or —(ch2)2or4, or r1 and r2, together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 6-membered heterocyclyl is optionally substituted by two hydroxy substituents; r3 and r4 are each independently hydrogen or methyl; and n is an integer having a value of 5 or 6, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment or prevention of various disorders, for example the treatment or prevention of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

Integrated health data capture and analysis system

The present invention provides an integrated health care surveillance and monitoring system that provides real-time sampling, modeling, analysis, and recommended interventions. The system can be used to monitor infectious and chronic diseases.
Theranos, Inc.

Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway

The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the nrp-1/obr signaling pathway..
Universite De Bourgogne

Method for treating infectious diseases using emissive energy

The present invention relates to the treatment of infectious diseases, specifically by extracorporeally eradicating the pathogen. This invention comprises methods for the extracorporeal treatment of infectious diseases that will remove infectious pathogens (leukemia cells, bacteria, viruses, or fungi causing a septicemia, metastatic cancer cells, target protein, viruses, parasites, fungi and prions) in humans by targeting such pathogens with a laser or other high-energy source of emissive radiation.
Marv Enterprises, Llc

Infectious laryngotracheitis virus (iltv) vaccine using recombinant newcastle disease virus vector

In this study, for the first time, protective efficacy of gd against iltv challenge was evaluated. Immunization with recombinant newcastle disease virus expressing iltv gd induced a higher level of neutralizing antibodies and offered complete protection to chickens against lethal iltv challenge.
University Of Maryland

Methods of measuring antigen-specific t cells

Provided herein are methods and kits for assaying antigen-specific t cell responses, such as rare autoantigen-specific t cell responses, by measuring a level of ip-10 in a sample from a subject having or suspected of having an autoimmune disease, an allergy, an infectious disease or condition, or an adverse immune condition caused by administration of an isolated, recombinant or synthetic protein or peptide. Also provided herein are methods and kits for assaying a t cell response to an antigen peptide, such as an islet autoantigen peptide, such as measuring a t cell response to at least one antigen peptide, such as an islet autoantigen peptide, in a sample from a subject, such as one having or suspected of having type 1 diabetes (tid), celiac disease or both..
Immusant, Inc.

Methods of detecting signatures of disease or conditions in bodily fluids

Methods and compositions for diagnosing the presence of a cancer cell in an individual are provided. Methods and compositions for identifying a tumor-specific signature in an individual having cancer are also provided.
President And Fellows Of Harvard College

Bacterial phospholipase inhibitors as modulator of colonic bacterial flora

The present invention relates to the field of gastroenterology and, more particular, to the field of intestinal diseases. More specifically, it concerns uses and methods for the treatment of inflammatory bacterial diseases of the intestine.
Universitaetsklinikum Heidelberg

Compositions having means for targeting at least one antigen to dendritic cells

A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a cpg oligodeoxynucleotide and/or a cpg-like oligodeoxynucleotide. This composition can used to treat cancers, infectious diseases caused by bacterial, viral, fungal, parasitic or protozoan infections, allergies and/or autoimmune diseases..
Universite Paris Descartes

Novel bacteriophage and composition comprising same

The present invention relates to a novel bacteriophage Φcj25 (kccm11463p) and a composition comprising the same as an active ingredient. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by avian pathogenic escherichia coli (apec) of birds by using the bacteriophage Φcj25 (kccm11463p) or the composition..
Cj Cheiljedang Corporation

Chimeric viruses presenting non-native surface proteins and uses thereof

The present invention provides chimeric negative-stand rna viruses that allow a subject, e.g., an avian, to be immunized against two infectious agents by using a single chimeric virus of the invention. In particular, the present invention provides chimeric influenza viruses engineered to express and incorporate into their virions a fusion protein comprising an ectodomain of a protein of an infectious agent and the transmembrane and cytoplasmic domain of an influenza virus protein.
Icahn School Of Medicine At Mount Sinai

Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin m (igm)

Compositions and methods of the present invention prevent, inhibit or reduce the toxic effects of proteins and toxins secreted from microbes. A method for neutralizing microbial protein products in a subject comprises administering a composition to the subject, said composition comprising plasma-derived igm and optionally one or more excipients in a pharmaceutical carrier, wherein the composition is administered in an amount effective to neutralize the microbial protein products..
Grifols Worldwide Operations Limited

Multi-functional mucosal vaccine platform

An immunogenic fusion protein for use as a mucosal vaccine is provided, which includes: i) one or more fcyri-binding domains; ii) one or more antigens from one or more infectious disease organisms; and iii) one or more fcrn-binding domains.. .
University Of Washington

Nkt cell ligands and methods of use

Alpha-glycosylceramide compounds capable of activating nkt cells and compositions thereof are disclosed. Methods for activating nkt cells, methods of stimulating an immune response in a subject, and methods of treating cancer, infectious diseases, autoimmune diseases and disorders, or allergy diseases or disorders with the compounds and compositions are also disclosed..
Brigham Young Unversity

Novel macrocyclic compounds

The present invention relates to novel macrocyclic compounds of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i)..
Bayer Pharma Aktiengesellschaft

Methionine analogs and methods of using same

Provided are methionine analogs which may be useful for inhibiting protein synthesis, inhibiting microbial growth and/or treating infectious diseases. In some instances, the analogs exhibit bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and/or antiviral properties.
Bioxiness Pharmaceuticals, Inc.

Thermomechanical decontamination infectious waste treatment

An infectious waste treatment system and method for decontaminating infectious waste employ a thermal friction extruder (20) in which first and second interleaved counter-rotatable augers (40, 42) include reverse pitch flight sections (62, 72) that urge waste material in a direction opposite to that of the flow stream and into engagement with the back sides of friction plates (50, 52). This increases the amount of heat generated by the extruder.

Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates

The present invention is directed to a composition or vaccine composition comprising a) an adjuvant component comprising or consisting of at least one immunostimulatory nucleic acid sequence, complexed with a complexing agent; b) an antigen, preferably a protein or peptide antigen and/or a nucleic acid sequence encoding said antigen; and c) a carrier molecule for combined packaging the adjuvant component and the antigen. The present invention is also directed to the first medical use of such a composition or vaccine composition and to the second medical use of such a composition or vaccine composition or components thereof for the treatment of diseases, such as infectious or cancer or tumour diseases as defined herein.
Curevac Ag

Vaccine composition

An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (tlr4) agonist, a toll-like receptor 2/6 (tlr2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof..
Nitto Denko Corporation

Method for enhancing immune response in the treatment of infectious and malignant diseases

The present invention pertains to a new approach for the treatment of infectious and malignant diseases. The present invention provides new dna and protein vaccines for the treatment of infectious and malignant diseases through enhancing immune response..
Taipei Veterans General Hospital

High throughput methods for virus quantification

This invention relates to high throughput methods of determining a viral titer. The instant invention addresses the need for a more rapid and cost effective method of quantitating infectious viral particles in a sample..
Merial Inc.

T-cell redirecting bispecific antibodies for treatment of disease

The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.
Ibc Pharmaceuticals, Inc.

Salts and prodrugs of 1-methyl-d-tryptophan

Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.. .
Newlink Genetics, Corp.

Combination therapy for inducing immune response to disease

The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies.
Ibc Pharmaceuticals, Inc.

System and contamination testing of high-touch surfaces

Methods and materials as may be utilized to provide consistent contamination testing of surfaces are described. The methods are based upon the designation of particular test zones on surfaces at risk of contamination by infectious agents.
Level 11, Llc

Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof

The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mrna containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells..
Tapimmune Inc.

Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group

The present invention relates to 5-fluoro pyrimidine derivatives containing a sulfondiimine group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i)..
Bayer Pharma Aktiengesellschaft

Compositions and methods of preparing leptospira

The present invention includes compositions and methods of preparing flagellar-coiling protein 1 (fcp1)-deficient leptospira bacterium. In one aspect, the invention includes an isolated, flagellar-coiling protein 1 (fcp1)-deficient leptospira bacterium.
Yale University

Combination of vaccination and ox40 agonists

The present invention relates to a vaccine/agonist combination comprising an rna vaccine comprising at least one rna comprising at least one open reading frame (orf) coding for at least one antigen and a composition comprising at least one ox40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination.
Curevac Ag

Inhibition of hypoxia-inducible factor activity with carica papaya extracts

An extract of carica papaya leaves obtained from a plant of age six months and younger from the date of germination of the seed is used as an inhibitor of hif to effectively block hypoxia-inducible factor (hif) function and methods of use thereof. More specifically it relates to the use of the carica papaya plant extract to eliminate unwanted cells by inhibiting hif in the prevention and treatment of hypoxia-related conditions and diseases such as inflammatory diseases, vascular diseases, cancer and infectious diseases.
Universiti Putra Malaysia

Topical compositions comprising extract of coriolus versicolor for autoimmunity enhancement

The present invention provides a topical composition comprising extract from coriolus versicolor for use for preventing and/or treating by vaginal or cervical administration of a vaginal or cervical disorder which is caused by an infectious agent, in particular, human papiloma virus infections and related disorders, including cervical cancer. The composition of the invention acts enhancing genital immunity against infectious agents and re-epithelising damaged tissue..
Procare Health Iberia, S.l.

Benzazepine dicarboxamide compounds

Wherein r1 to r4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Continuous directed evolution

The invention provides systems, methods, reagents, apparatuses, vectors, and host cells for the continuous evolution of nucleic acids. For example, a lagoon is provided in which a population of viral vectors comprising a gene of interest replicates in a stream of host cells, wherein the viral vectors lack a gene encoding a protein required for the generation of infectious viral particles, and wherein that gene is expressed in the host cells under the control of a conditional promoter, the activity of which depends on a function of the gene of interest to be evolved.
President And Fellows Of Harvard

Infectious waste treatment system

A method and apparatus for infectious waste treatment. First, the infectious waste may be shredded into a mixture of liquid and shredded solid waste, then the mixture may be poured into a plurality of perforated bags.

Methods of imaging with ga-68 labeled molecules

The present application discloses compositions and methods of use of 68ga labeled molecules. Preferably, the 68ga is attached to a peptide targetable construct and is used in a pretargeting technique with a bispecific antibody (bsab).
Immunomedics, Inc.

Methods and compositions for gene delivery to on bipolar cells

Disclosed are capsid-modified raav expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated raav vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian eye.
University Of Florida Research Foundation, Inc.

Methods and compositions for treating cancer and infectious diseases

The invention relates to compositions comprising a cd4 lymphocyte depleting agent; and methods of using the compositions to treat, prevent, reduce the severity of and/or slow the progression of a condition in a subject. The invention also relates to use of combinations of a cd4 lymphocyte depleting agent and at least one additional agent to treat, prevent, reduce the severity of and/or slow the progression of a condition in a subject.
Cedars-sinai Medical Center

Peptide-mediated delivery of active agents across the blood-brain barrier

Provided herein are methods for transporting an infectious agent (e.g., a virus) across the blood-brain barrier (bbb). For example, the methods provided herein can be used to make a non-human animal model of an infectious brain disease.
Mayo Foundation For Medical Education And Research

Probiotics for use in expecting female mammals for enhancing the immunity of their offspring

The present invention relates to the use of probiotic on expecting female mammals to boost the immune status of an offspring. The use can induce an enhanced response of the offspring after birth to an infectious antigenic exposure.
Nestec S.a.

Qiagen Gmbh

. .

Removable trap for lavatory sinks

A removable trap for lavatory sinks is provided to enable new technologies to be incorporated into just the water trap portion of the sink trap to maximize the performance of the trap in infection control, while at the same time preserving the trap performance features demanded by major building codes. While a traditional p-trap requires the removal of the entire trap for cleaning or replacement, the removable trap presented in this application allows for easy removal of just the u-bend portion of the trap.

Compositions and methods for modulating an immune response

Described herein are compositions for increasing il-12 production comprising igg or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing il-12 production comprising an agent that inhibits signaling mediated by interaction between fcrn and igg and uses of said compositions for treating autoimmune diseases.
The Brigham And Women's Hospital, Inc.

5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group

The present invention relates to 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group of general formula (i) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (i)..
Bayer Pharma Aktiengesellschaft

Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer

Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
Immunomedics, Inc.

Method for producing dry extracts

The invention relates to a method for producing dry extracts of plants and to pharmaceutical preparations containing the same, more particularly phytopharmaceuticals, which contain at least one ethanolic/aqueous extract of a plant (drug), the plants being selected from the group consisting of: rumicis herba; verbena officinalis; sambucus nigra; primula veris; and gentiana lutea and mixtures thereof. The invention further relates to a pharmaceutical for treating inflammatory and/or infectious diseases of the nose and throat area and/or the nasal sinuses, as well as the use thereof..
Bionorica Se